



- 2014 – 2016 Chief Scientific Officer, MycoMed Technologies, Baltimore, MD  
 2016 – 2020 President, American Society for Clinical Investigation  
 2016 – 2023 Co-Founder, Chief Executive Officer, Director Pearl Diagnostics, Inc.  
 (previously MycoMed Technologies, LLC)

## **Education and training**

### **Undergraduate**

1983–1988 BS, California State University, Chico, CA; Microbiology

### **Doctoral/graduate**

1989–1993 MD, Hahnemann University School of Medicine, Philadelphia, PA; Medicine

2016–2018 MBA, Massachusetts Institute of Technology, Boston, MA

### **Postdoctoral training and fellowships**

1993–1994 Internship in Internal Medicine, Duke University School of Medicine, Durham, NC

1994–1996 Resident in Internal Medicine, Duke University School of Medicine, Durham, NC

1996 Assistant Chief Resident, Internal Medicine, Duke University, Durham, NC

1996 Certificate, Biometry, Duke University

1996–1998 University of Washington, Seattle; Fellowship, Infectious Diseases (ID)

1996–1998 Fred Hutchinson Cancer Research Center, Seattle; Fellowship, Transplant and Oncology Infectious Diseases

### **Other**

1983 Molecular Diseases Branch, National Heart, Lung, and Blood Institutes, NIH Normal Volunteer, Research Assistant (P.I. Bryan Brewer). Molecular analysis of the human apolipoprotein C-II gene.

1988 Palo Alto Medical Research Institute, Stanford University, Palo Alto, CA  
 Research Assistant (P.I. Jack Remington)  
 Molecular analysis of genes encoding immunogenic proteins in *Toxoplasma gondii*.

1989 Dept. of Biochemistry, Georgetown Univ. School of Med, Wash D.C.  
 Research Assistant (P.I. Mark Smulson)  
 Role of poly(ADP-ribose)polymerase in B cell V(D)J recombination.

1992 Lymphoma Biology Section, Pediatric Branch, National Cancer Institutes, NIH  
 Pre-doctoral student (P.I. Ian Magrath)  
 Development of in situ hybridization assays for Epstein Barr Virus

## **PUBLICATIONS**

### **Original Research (trainees underlined)**

1. Fojo SS, Stalenhoef AF, **Marr K**, Gregg RE, Ross RS, HB Brewer. A deletion mutation in the ApoC-II gene (Apo C-II Nijmegen) of a patient with a deficiency of apolipoprotein C II. J Biol Chemistry. 1988; 263(34):17913-6.

2. **Marr KA**, Sexton DJ, Conlon PJ, Corey GR, Schwab SJ, and KB Kirkland. Catheter- related Bacteremia and outcome of attempted catheter salvage in patients undergoing hemodialysis. *Ann Intern Med.* 1997; 127:275-80.
3. Fowler VG, Li J, Corey GR, Boley J, **Marr KA**, Gopal AK, Kong LK, Gottlieb G, Donovan GL, Sexton DJ, Ryan T. Role of echocardiography in evaluation of patients with *Staphylococcus aureus* bacteremia: experience in 103 patients. *J Amer Col Card.* 1997; 30(4):1072-8.
4. **Marr KA**, White TC, van Burik J, Bowden RA. Development of fluconazole resistance in *Candida albicans* causing disseminated infection in a patient undergoing marrow transplantation. *Clin Infect Dis.* 1997; 25:908-10.
5. Fowler VG, Sanders LL, Sexton DJ, Kong LK, **Marr, KA**, Gopal AK, Gottlieb GS, McClelland S, Corey GR. Outcome of *Staphylococcus aureus* bacteremia according to compliance with infectious diseases specialist recommendations: experience with 244 patients. *Clin Infect Dis.* 1998; 27(3): 478-486.
6. **Marr KA**, Fowler VG, Gopal A, Sexton DJ, Conlon PJ, Corey GR. Incidence and outcome *Staphylococcus aureus* bacteremia in hemodialysis patients. *Kidney International.* 1998; 54:1684-1689.
7. **Marr KA**, Lyons C, Bowden RA, White TC. Rapid, transient fluconazole resistance in *C. albicans* is associated with increased expression of *CDR*. *Antimicrob Agents Chemother.* 1998; 42(10): 2584-2589.
8. **Marr KA**, Rustad TR, Rex JH, White TC. The trailing endpoint phenotype in antifungal susceptibility testing is pH dependent. *Antimicrob Agents Chemother.* 1999; 43(6): 1383- 1386.
9. White TC, **Marr KA**, Bowden RA. Clinical, cellular and molecular factors that contribute to antifungal drug resistance. *Clin Micro Rev.* 1998; 11(2):382-402.
10. Gottlieb GS, Fowler VG, Kong LK, McClelland RS, Gopal A, **Marr KA**, Li J, Sexton DJ, Glower D, Corey GR. *Staphylococcus aureus* bacteremia in the surgical patient: a prospective analysis of 73 post-operative patients who developed *Staphylococcus aureus* bacteremia at a tertiary care facility. *J Amer Col Surg.* 2000; 190:50-57.
11. **Marr KA**, Seidel K, White TC, Bowden RA. Candidemia in blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole *J Infect Dis.* 2000; 181:309-16.
12. Gopal AK, Fowler VG, Shah M, Gesty-Palmer D, **Marr KA**, McClelland RS, Kong LK, Gottlieb GS, Lanclos K, Li J, Sexton DJ, Corey GR. Prospective analysis of *Staphylococcus aureus* bacteremia in nonneutropenic adults with malignancy. *J Clin Oncol.* 2000; 18(5):1110.
13. **Marr KA**, Seidel K, Slavin MA, Bowden RA, Schoch HG, Flowers MED, Corey L, Boeckh M. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. *Blood.* 2000; 96 (6):2055.
14. **Marr KA**, Lyons CN, Ha K, Rustad TR, White TC. Inducible azole resistance associated with a heterogeneous phenotype in *Candida albicans*. *Antimicrob Agents Chemother.* 2001. 46(1): 52.
15. Storek J, Dawson M, Storer B, Stevens-Ayers T, Maloney D, **Marr KA**, Witherspoon R, Flowers M, Storb R, Appelbaum F, Boeckh M. Immune reconstitution after allogeneic marrow transplantation compared to blood stem cell transplantation. *Blood.* 2001. 97:3380- 3389.
16. **Marr KA**, Khodadoust M, Black M, Balajee SA. Early events in macrophage killing of *Aspergillus fumigatus* conidia: Development of a new flow cytometric viability assay. *Clin Lab Immunol.* 2001; 8(6):1240-7.
17. **Marr KA**, Carter R, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients *Clin Infect Dis.* 2002; 34:909-17.
18. Zerr DM, Garrison M, **Marr KA**, Christakis DA. A meta-analysis of fluconazole versus

- amphotericin B for treatment of documented invasive *Candida* infections. J Clin Out Man. 2002; 9(4): 191-96.
19. Yu J, **Marr KA**, Holland SM, Bennett JE. Efficacy of fluconazole, caspofungin and amphotericin B in *Candida glabrata*-infected p47<sup>phox(-/-)</sup> knockout mice. Antimicrob Agents Chemother. 2002; 46: 1240-45.
  20. Crippa F, Holmberg L, Carter RA, Hooper H, **Marr KA**, Bensinger W, Chauncey T, Corey L, Boeckh M. Infectious complications after autologous CD34 selected peripheral blood stem cell transplantation. Biol Blood Marrow Transplant; 8:281-89 (2002).
  21. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern W, **Marr KA**, Ribaud P, Lortholary O, Sylvester R, de Pauw B. Randomized comparison of voriconazole and amphotericin B in primary therapy of invasive aspergillosis. A collaborative study of the EORTC invasive fungal infection group and the global aspergillosis study group. New Engl J Med. 2002; 347:408-15.
  22. Balajee SA, **Marr KA**. A conidial viability assay for rapid susceptibility testing of *Aspergillus* species. J Clin Microbiol. 2002; 40(8):2741-5.
  23. Junghanss C, **Marr KA**, Carter RA, Sandmaier B, Maris MB, Maloney DG, Chauncey T, Storb R. Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study. Biol Blood Marrow Transplant. 2002; 8(9):512- 20.
  24. **Marr KA**, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risks. Blood. 2002; 10(13):4358-66.
  25. Novicki T, LiFei K, Giese R, **Marr KA**, Bui UT, Limaye A. Genetic diversity among clinical isolates of *Acremonium strictum* determined during an investigation of a fatal mycosis. J Clin Microbiol. 2003; 41:2623 28.
  26. Fukuda T, Boeckh M, Carter R, Sandmaier B, Maris M, Maloney D, Martin P, Storb R, **Marr KA**. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplantation after nonmyeloablative conditioning: risks and outcomes. Blood. 2003; 102:827-33.
  27. **Marr KA**, Balajee SA, Hawn TR, Ozinsky A, Pham U, Aderem A, Akira S, Liles WC. Differential role of MyD88 in macrophage-mediated responses to opportunistic fungal pathogens. Infect Immun. 2003; 71:5280-5286.
  28. Imhof A, Balajee SA, **Marr KA**. Agardilution: A new method to assess *Aspergillus* susceptibility to caspofungin. J Clin Microbiol. 2003; 41(12): 5683- 88.
  29. Perfect J, **Marr KA**, et al. Voriconazole for treatment of refractory infections caused by unusual fungi. Clin Infect Dis. 2003; 36:1122-31.
  30. **Marr KA**, Crippa F, Leisenring W, Hoyle M, Boeckh M, Balajee SA, Musher B, Corey L. Itraconazole vs. fluconazole for antifungal prophylaxis in allogeneic HSCT patients. Blood. 2004; 103: 1527-33.
  31. **Marr KA**, Leisenring W, Crippa F, Slattery JT, Corey L, Boeckh M, McDonald GB. Cyclophosphamide metabolism is affected by azole antifungals. Blood. 2004; 103: 1557- 59.
  32. Balajee SA, Weaver M, Imhof A, **Marr KA**. *Aspergillus fumigatus* variant with decreased susceptibilities to multiple antifungals. Antimicrob Agents Chemother. 2004; 48(4) 1197- 1203.
  33. Bennett JE, Izumikawa K, **Marr KA**. Mechanism of rapid increase in *C. glabrata* fluconazole resistance during prophylaxis. Antimicrob Agents Chemother. 2004; 48(5):1773-7.
  34. Nucci M, **Marr KA**, Queiroz-Telles F, Martins CA, Trabasso P, Costa S, Voltarelli JC, Colombo AL, Imhof A, Pasquini R, Maiolino A, Souza CA, Anaissie E. *Fusarium* infection in hematopoietic stem cell transplant (HSCT) recipients. Clin Infect Dis. 2004; 38:1237-42.
  35. Fukuda T, Boeckh M, Guthrie KA, Owens S, Mattson DK, Wald A, Corey L, Storb RF, **Marr KA**. Invasive Aspergillosis Before Allogeneic Hematopoietic Stem Cell Transplantation: 10-year

- experience at a single transplant center. *Biol Blood Marr Trans*. 2004; 19(7): 494-503.
36. Steinbach WJ, Benjamin DK, Kontoyiannis DP, Perfect JR, Lutsar I, **Marr KA**, Lionakis MS, Torres HA, Jafri H, Walsh TJ. Infections due to *Aspergillus terreus*: A multicenter retrospective analysis of 83 cases. *Clin Infect Dis*; 2004; 39:192-8.
  37. **Marr KA**, Balajee SA, Leisenring W, Weaver B, Tabouret M, Bentsen C, Walsh TJ. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of aspergillosis: Variables that affect performance. *J Infect Dis*. 2004; 190:641-9.
  38. Imhof A, Balajee SA, Fredricks DN, Englund JA, **Marr KA**. Breakthrough fungal infections in stem cell transplant patients receiving voriconazole. *Clin Infect Dis*. 2004; 39: 743-6.
  39. **Marr KA**, Boeckh M, Kim HW, Carter RA, Corey L. Combination antifungal therapy for invasive aspergillosis. *Clin Infect Dis*. 2004; 39: 797-802.
  40. Redding SW, **Marr KA**, Kirkpatrick WR, Coco BJ, Patterson TF. *Candida glabrata* sepsis secondary to oral colonization in bone marrow transplantation. *Med Mycology*. 2004; 42:479-81.
  41. Musher B, Fredricks D, Leisenring W, Balajee SA, **Marr KA**. *Aspergillus galactomannan* EIA and quantitative PCR for diagnosis of aspergillosis in HCT patients using bronchoalveolar lavage. *J Clin Microbiol*. 2004; 42(12): 5517-22.
  42. Sancak B, Rex JH, Chen E, **Marr KA**. Comparison of PCR- and *HinfI* restriction endonuclease-based methods for typing of *Candida krusei* isolates. *J Clin Microbiol*. 2004; 42(12): 5889-91.
  43. **Marr KA**, Hachem R, Papanicolaou G, Somani J, Arduino JM, Lipka CJ, Ngai AL, Kartsonis N, Chodakewitz J, Sable C. Retrospective study of the hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporin A. *Transpl Infect Dis*. 2004; 6:110-16.
  44. Balajee SA, Imhof A, Griboskov JL, **Marr KA**. Determination of antifungal drug susceptibilities of *Aspergillus* species by a fluorescence-based microplate assay. *J Antimicrob Chemother*. 2005; 55: 102-105.
  45. Balajee SA, Griboskov JL, Hanley E, Nickle D, **Marr KA**. *Aspergillus lentulus sp. nov.*: a new sibling species of *A. fumigatus*. *Eukaryotic Cell*. 2005; 4: 625-632.
  46. **Marr KA**, Laverdiere M, Gugel A, Leisenring W. Antifungal therapy decreases sensitivity of the Platelia *Aspergillus galactomannan* enzyme immunoassay. *Clin Infect Dis*. 2005; 40(12):1762-9.
  47. Gersuk G, Hiraoka A, **Marr KA**. Human monocytes differentiate into macrophages under the influence of KPB-M15 conditioned medium. *J Immunol Methods*. 2005; 299: 99-106.
  48. Morgan J, Wannemuehler KA, **Marr KA**, Hadley S, Kontoyianis DP, Walsh TJ, Fridkin SK, Pappas PG, Warnock DW. Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. *Medical Mycology*. 2005; Supplement 43, S49-S58
  49. Bok JW, Balajee SA, **Marr KA**, Andes D, Fog Nielsen K, Frisvad JC, Keller NP. Lae A, a regulator of morphogenetic fungal virulence factors. *Euk Cell*. 2005; 4(9):1574-82.
  50. Upton A, Gugel A, Leisenring W, Limaye A, Alexander B, Hayden R, **Marr KA**. Reproducibility of low galactomannan enzyme immunoassay index values tested in multiple laboratories. *J Clin Microbiol*. 2005; 43 4796-4800.
  51. Balajee SA, Griboskov J, Brandt M, Ito J, Fothergill A, **Marr KA**. Mistaken identity: *Neosartorya pseudofischeri* and its anamorph masquerading as *Aspergillus fumigatus*. *J Clin Microbiol*. 2005; 43(12):5996-9.
  52. Greenberg RN, Raad I, Mullane K, Abzug M, Anstead G, Herbrecht R, Langston A, **Marr KA**, Schiller G, Schuster M, van Burik, J-AH, Wingard, JR, Gonzalez, CE, Corcoran G, Kryscio RJ, Hare R. Posaconazole as Salvage for Zygomycosis. *Antimicrob Agents Chemother*. 2006; 50(1):126-33.
  53. Panackal AA, Imhof A, Hanley EW, **Marr KA**. *Aspergillus ustus* infections among transplant recipients. *Emerging Infect Dis*. 2006; 12(3): 403-08.

54. Gersuk GM, Underhill DM, Zhu L, **Marr KA**. Dectin-1 and Toll-like receptors permit macrophages to distinguish between different *Aspergillus fumigatus* cellular states. *J Immunology*. 2006; 176:3717-24.
55. Panackal AA, Gribskov JL, Staab JF, Kirby K, Rinaldi M, **Marr KA**. Clinical significance of azole antifungal drug resistance in *Candida glabrata*. *J Clin Microbiol*. 2006; 44(5): 337-49.
56. Sheppard DC, **Marr KA**, Fredricks DN, Chiang LY, Doedt T, Filler SG. Comparison of three methodologies for the determination of pulmonary fungal burden in experimental murine aspergillosis. *Clin Microbiol Infect*. 2006; 12: 376-380.
57. Hakke M, Staab J, **Marr KA**. Emergence of *Candida krusei* with reduced susceptibility to caspofungin during therapy. *Antimicrob Agents Chemother*. 2006; 50:2522-2524.
58. Denning DW, **Marr KA**, Lau WM, Facklam DP, Ratanatharathorn V, Becker C, Ullman AJ, Seibel NL, Flynn PM, van Burik JA, Buell DN, Patterson TF. Micafungin (FK-463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. *J Infect*. 2006; 53:337-349.
59. Balajee SA, Nickle D, Varga J, **Marr KA**. Molecular studies reveal frequent misidentification of *Aspergillus fumigatus* by morphotyping. *Euk Cell*. 2006; 5:1705-1712.
60. Allard J, Poynter ME, **Marr KA**, Cohn L, Rincon M, Whittaker L. *Aspergillus fumigatus* generates an enhanced Th2-biased immune response in mice with defective cystic fibrosis transmembrane conductance regulator. *J Immunology*. 2006; 177:5186-5194.
61. Martino R, Parody F, Fukuda T, Maertens J, Theunissen K, Ho A, Mufti GJ, Kroger N, Zander AR, Heim D, Palusaewska M, Selleslag D, Steinerova K, Ljungman P, Cesaro S, Nihtinen A, Cordonnier C, Vazquez L, Lopez-Duarte M, Lopez J, Caberra R, Rovira M, Neuburger S, Cornely O, Hunter AE, **Marr KA**, Donrbusch HJ, Einsele H. Impact of the intensity of the pre-transplant conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: a retrospective survey of the infectious diseases working party of the European group for blood and marrow transplantation. *Blood*. 2006; 108(9):2928-36.
62. Bok JW, Chung D, Balajee SA, **Marr KA**, Andes D, Nielsen KF, Frisvad JC, Kirby KA, Keller NP. GliZ, a transcriptional regulator of gliotoxin biosynthesis, contributes to *Aspergillus fumigatus* virulence. *Infect and Immunity*. 2006; 74(12): 6761-8.
63. Upton A, Kirby K, Carpenter P, Boeckh M, **Marr KA**. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. *Clin Infect Dis*. 2007; 44(4): 531-40.
64. Kahn, JN, Garcia-Effron G, Hsu M, Park S, **Marr KA**, Perlin DS. Acquired echinocandin resistance in a *Candida krusei* isolate due to modification of glucan synthase. *Antimicrob Agents Chemother*. 2007; 51(5): 1876-8.
65. Upton A, McCune J, Kirby KA, Leisenring W, McDonald G, Batchelder A, **Marr KA**. Fluconazole coadministration concurrent with cyclophosphamide conditioning may reduce regimen related toxicity post-myeloablative hematopoietic cell transplantation. *Biol Blood Marrow Transplantation*. 2007; 13(7): 760-4.
66. Upton A, Fraser JA, Kidd SE, Bretz C, Bartlett KH, Heitman J, **Marr KA**. First contemporary case of human infection with *Cryptococcus gattii* in Puget Sound: evidence of spread of the Vancouver Island outbreak. *J Clin Microbiol*. 2007; 45(9): 3086-8.
67. Horn DL, Fishman JA, Steinbach WJ, Anaissie EJ, **Marr KA**, Olyaei AJ, Pfaller MA, Weiss MA, Webster KM, Neofytos D. Presentation of the PATH Alliance® registry for prospective data collection and analysis of the epidemiology, therapy and outcomes of invasive fungal infections. *Diag Microbiol and Infect Dis*. 2007; 59(4): 407-14.
68. Horn D, Neofytos D, Fishman J, Steinbach W, Anaissie E, **Marr KA**, Olyaei A. Use of the PATH Alliance database to measure adherence to IDSA guidelines for therapy of candidemia. *Eur J Clin Microbiol Infect Dis*. 2007; 26(12): 907-14.

69. Barnes PD, **Marr KA**. Risks, diagnosis and outcomes of invasive fungal infections in haematopoietic stem cell transplant recipients. *Brit J Haematol*. 2007; 139(4): 519-31.
70. Gersuk GM, Razai LW, **Marr KA**. Methods of in vitro macrophage maturation confer variable inflammatory responses in association with altered expression of cell surface dectin-1. *J Immunol Methods*. 2008; 329: 157-166.
71. Bretz C, Gersuk G, Knoblaugh S, Chaudhary N, Randolph-Habecker J, Hackman R, Staab J, **Marr KA**. MyD88-signaling contributes to early pulmonary responses to *Aspergillus fumigatus*. *Infect Immun*. 2008; 76(3): 952-8.
72. Zaas AK, Liao G, Chien JW, Weinberg C, Shore D, Giles SS, **Marr KA**, Usuka J, Burch L, Perera L, Perfect JR, Peltz G, Schwartz DA. Plasminogen alleles influence susceptibility to invasive aspergillosis. *PLoS Genetics* 2008 4(6):e1000101.
73. Scott BL, Park JY, Deeg J, **Marr KA**, Boeckh M, Chauncey TR, Appelbaum FR, Storb R, Storer B. Storer. Pre-transplant neutropenia is associated with increased post-transplant mortality in patients with myelodysplastic syndromes. *Biol Blood Marrow Transplant*. 2008; 14(7): 799-806.
74. Garcia-Vidal C, Upton A, Kirby KA, **Marr KA**. Epidemiology of invasive mould infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplant. *Clin Infect Dis* 2008; 47(8): 1041-50.
75. Bochud PY, Chien JW, **Marr KA**, Leisenring WM, Upton A, Janer M, Rodrigues SD, Li S, Hansen JA, Zhao LP, Aderem A, Boeckh M. Association of donor Toll-like Receptor 4 polymorphisms with susceptibility to invasive aspergillosis in hematopoietic cell transplant recipients. *New Eng J Med* 2008; 359(17): 1766-77.
76. Neofytos D, Horn D, Anaissie E, Steinbach W, Olyaei A, Fishman J, Pfaller M, Chang C, Webster K, and **Marr KA**. Epidemiology and outcome of invasive fungal infections in adult hematopoietic stem cell transplant recipients: analysis of multicenter PATH alliance registry. *Clin Infect Dis* 2009; 48(3): 265-73.
77. Byrnes EJ, Bildfell R, Frank SA, Mitchell TG, **Marr KA** and Heitman J. Molecular evidence that the Vancouver Island *Cryptococcus gattii* outbreak has expanded into the United States Pacific Northwest. *J Infect Dis* 2009; 199(7): 1081-6.
78. Mielcarek M, Storer BE, Boeckh MJ, Carpenter PA, McDonald GB, Deeg J, Nash RA, Flowers MED, Doney K, Lee S, **Marr KA**, Furlong T, Storb R, Appelbaum FR, Martin PJ. Initial therapy of acute graft-vs.-host disease with “low dose” prednisone does not compromise patient outcomes”. *Blood* 2009; 113(13):2888-94.
79. Datta K, Bartlett KH, **Marr KA**. *Cryptococcus gattii* emergence in Western North America: exploitation of a novel ecological niche. *Inter Persp Infect Dis* 2009; 176532.
80. Kontoyiannis DP, Ratanatharathorn V, Young JA, Raymond J, Laverdiere M, Denning DW, Patterson TF, Facklam D, Kovanda L, Arnold L, Lau W, Buell D, **Marr KA**. Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis. *Transpl Infect Dis* 2009; 11(1): 80-93.
81. Horn DL, Neofytos D, Anaissie EJ, Fishman JA, Steinbach WJ, Olyaei AJ, **Marr KA**, Pfaller MA, Chang CH, Webster KM. Epidemiology and outcomes of 2019 patients with candidemia: data from the PATH Alliance Registry. *Clin Infect Dis* 2009; 48: 1695-1703.
82. Davis JA, Horn DL, **Marr KA**, Fishman JA. Central nervous system involvement in cryptococcal infection in individuals after solid organ transplantation or with AIDS. *Transplant Infect Dis* 2009; 48(12): 1695-703.
83. Staab JF, Balajee SA, **Marr KA**. *Aspergillus* section *Fumigati* typing by PCR-RFLP. *J Clin Microbiol* 2009; 47(7) 2079-83.
84. Datta K, Bartlett K, Baer R, Byrnes E, Galanis E, Heitman J, Hoang L, Leslie M, MacDougall L, Morshed M, and **Marr KA**. Spread of *Cryptococcus gattii* into Pacific Northwest Region of the United States. *Emerg Infect Dis* 2009; 176532.

85. **Marr KA**, Bow E, Chiller T, Maschmeyer G, Ribaud P, Segal B, Steinbach W, Wingard JR, and Nucci M; Center for International Blood and Marrow Transplant Research; National Marrow Donor Program; European Blood and Marrow Transplant Group; American Society of Blood and Marrow Transplantation; Canadian Blood and Marrow Transplant Group; Infectious Disease Society of America; Society for Healthcare Epidemiology of America; Association of Medical Microbiology and Infectious Diseases Canada; Centers for Disease Control and Prevention. Fungal infection prevention after hematopoietic cell transplantation. *Bone Marrow Transplantation* 2009; 44: 483-87.
86. Balajee SA, Kano R, Baddley JW, Moser SA, **Marr KA**, Alexander BD, Andes D, Kontoyiannis DP, Perrone G, Peterson S, Brandt ME, Pappas PG, and Chiller T. Molecular identification of *Aspergillus* species: Transplant Associated Infection Surveillance Network (TRANSNET). *J Clin Microbiol* 2009; 47(10): 3138-41.
87. Baddley JW, **Marr KA**, Andes DR, Walsh TJ, Kauffman CA, Kontoyiannis DP, Ito J, Balajee SA, Pappas PG, and Moser SA. Susceptibility patterns of *Aspergillus* isolates from the Transplant Associated Infection Surveillance Network (TRANSNET). *J Clin Microbiol* 2009 47(10): 3271-5.
88. Neofytos D, Fishman JA, Horn D, Anaissie E, Chang C-H, Olyaei A, Pfaller M, Steinbach WJ, Webster KM and **Marr KA**. Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients. *Transplant Infect Dis* 2010 12(3): 220-9.
89. Kontoyiannis DP, **Marr KA**, Park BJ, Alexander BD, Anaissie EJ, Walsh TJ, Ito J, Andes DR, Baddley JW, Brown JM, Brumble LM, Freifeld AG, Hadley S, Herwaldt LA, Kauffman CA, Knapp K, Lyon GM, Morrison VA, Papanicolaou G, Patterson TF, Perl TM, Schuster MC, Walker R, Wannemuehler KA, Wingard JR, Chiller TM, and Pappas PG. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the TRANSNET database. *Clin Infect Dis* 2010; 50: 1091-1100.
90. Pappas PG, Alexander BD, Andes DR, Hadley S, Kauffman CA, Freifeld A, Anaissie EJ, Brumble LM, Herwaldt L, Ito J, Kontoyiannis DP, Lyon GM, **Marr KA**, Morrison VA, Park BJ, Patterson TF, Perl TM, Oster RA, Schuster MG, Walker R, Walsh TJ, Wannemuehler KA, Chiller TM. Invasive fungal infections among organ transplant recipients: results of the transplant-associated infection surveillance network (TRANSNET). *Clin Infect Dis* 2010; 50: 1101-1111.
91. Sugui JA, Vinh DC, Nardone G, Shea YR, Chang YC, Zelazny AM, **Marr KA**, Holland SM, Kwon-Chung KJ. *Neosartorya udagawae* (*Aspergillus udagawae*), an emerging agent of aspergillosis: How different is it from *Aspergillus fumigatus*? *J Clin Microbiol* 2010; 48(1): 220-8.
92. Chaudhary N, Staab J, **Marr KA**. Healthy human T cell responses to recombinant *Aspergillus* antigens. *PLoS One* 2010; 5(2): e9036.
93. Baddley JW, Andes DR, **Marr KA**, Kontoyiannis DP, Alexander BD, Kauffman CA, Oster RA, Anaissie EJ, Walsh TJ, Schuster MG, Wingard JR, Patterson TF, Ito JI, Williams OD, Chiller T, Pappas PG. Factors associated with mortality in transplant patients with invasive aspergillosis. *Clin Infect Dis* 2010; 50(12): 1559-1567.
94. Panaackal AA, Li H, Kontoyiannis DP, Mori M, Perego CA, Boeckh M, **Marr KA**. Geoclimatic influences on invasive aspergillosis after hematopoietic stem cell transplantation. *Clin Infect Dis* 2010; 50(12): 1588-97.
95. Tsai HJ, Sammons LR, Zhang X, Suffis SD, Su Q, Myers TG, **Marr KA**, Bennett JE. Microarray and molecular analysis of the azole resistance mechanism in *Candida glabrata* oropharyngeal isolates. *Antimicrob Agents Chemother* 2010 54(8): 3308-17.
96. Kumar D, Michaels MG, Morris MI, Green M, Avery RK, Lui C, Danziger-Isakov L, Stosor V, Estabrook M, Gantt S, **Marr KA**, et al. on behalf of the AST H1N1 Collaborative Study Group. Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study. *Lancet Infect Dis* 2010; 10(8): 521-6.
97. Staab J, White T, **Marr KA**. Hairpin dsRNA does not trigger RNA interference in *Candida albicans* cells. *Yeast* 2011; 28(1): 1-8.
98. Wingard JR, Carter SL, Walsh TJ, Kurtzberg J, Small TN, Gersten ID, Mendizabal AM, Leather HL,



- Confer DL, Maziarz RT, Stadtmauer EA, Bolanos-Meade J, Brown J, Dipersio JH, Boeckh M, **Marr KA**. Randomized double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection (IFI) after allo hematopoietic cell transplantation (HCT). *Blood* 2010; 116(24): 5111-18.
99. Staab J, Kahn J, **Marr KA**. Differential *Aspergillus lentulus* echinocandin susceptibilities are Fksp Independent. *Antimicrob Agents Chemother* 2010; 54(12): 4992-8.
  100. Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorrow ML, Boeckh M, Martin PJ, Sandmaier BM, **Marr KA**, Appelbaum FR, Storb R, McDonald GB. Reduced mortality after allogeneic hematopoietic cell transplantation. *New Eng J Med*. 2010 363(22): 2091- 101.
  101. Lockhart SR, Zimbeck AJ, Baddley JW, **Marr KA**, Andes DR, Walsh TJ, Kauffman CA, Kontoyiannis DP, Ito JI, Pappas PG, Chiller T. In vitro susceptibility of *Aspergillus* to echinocandins: isolates from patients enrolled in the transplant-associated infection surveillance network. *Antimicrob Agents Chemother* 2011 55(8): 3944-6.
  102. Park BJ, Pappas PG, Wannemuehler KA, Alexander BD, Anaissie EJ, Andes DR, Baddley JW, Brown JM, Brumble LM, Friefeld AG, Hadley S, Herwaldt L, Ito JI, Kauffman CA, Lyon GM, **Marr KA**, Morrison VA, Papanicolaou G, Patterson TF, Perl TM, Schuster MG, Walker R, Wingard JR, Walsh TJ, Konyoyiannis DP. Invasive non-*Aspergillus* mold infections in transplant recipients, United States, 2001-2006. *Emerg Infect Dis* 2011. 17(10): 1855-64.
  103. Chaudhary N, Datta K, Askin FB, Staab JF, **Marr KA**. CFTR regulates epithelial cell response to *Aspergillus* and resultant pulmonary inflammation. *Am J Respir Crit Care Med* 2012 185(3): 301-10.
  104. Dierberg KL, **Marr KA**, Subramanian A, Nace H, Desai N, Locke JE, Zhang S, Diaz J, Chamberlain C, Neofytos D. Donor-derived organ transplant transmission of coccidioidomycosis. *Transpl Infect Dis* 2012; 14(3): 300-4.
  105. Neofytos D, Lombardi LR, Shields RK, Ostrander D, Warren L, Nguyen MH, Thompson CB, **Marr KA**. Administration of voriconazole in patients with renal dysfunction. *Clin Infect Dis* 2012; 54(7): 913-21.
  106. Fisher BT, Zaoutis TE, Park JR, Bleakeley M, Englund J, Kane C, Arceci RJ, Smith FO, Luan X, and **Marr KA**. Galactomannan antigen testing for diagnosis of invasive aspergillosis in pediatric hematology patients. *J Ped Infect Dis Soc*. 2012 1(2): 103-111.
  107. Alonso CD, Treadway SB, Hanna DB, Huff CA, Neofytos D, Carroll KC, **Marr KA**. Epidemiology and outcomes of *Clostridium difficile* infections in hematopoietic stem cell transplant recipients. *Clin Infect Dis* 2012; 54(8): 1053-63.
  108. Baddley JW, Andes DR, **Marr KA**, Kauffman CA, Kontoyiannis DP, Ito JI, Schuster MG, Brizendine KD, Patterson TF, Lyon GM, Boeckh M, Oster RA, Chiller T, Pappas PG. Antifungal therapy and length of hospitalization in transplant patients with invasive aspergillosis. *Med Mycol* 2012
  109. Steinbach WJ, **Marr KA**, Anaissie EJ, Azie N, Quan SP, Meier-Kriesche U, Apewokin S, and Horn DL. Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH Alliance registry. *J Infect* 2012
  110. Dufresne SF, Datta K, Li X, Dadachova E, Staab SF, Patterson TF, Feldmesser M, and **Marr KA**. Detection of urinary excreted fungal galactomannan-like antigens for diagnosis of invasive aspergillosis. *Plos One* 2012
  111. Neofytos D, Kobayashi K, Alonso CD, Cady-Reh J, Lepley D, Harris M, Desai N, Kraus E, Subramanian A, Treadway S, Ostrander D, Thompson C, **Marr KA**. Epidemiology, risk factors, and outcomes of *Clostridium difficile* infection in kidney transplant recipients. *Transp Infect Dis* 2012
  112. Neofytos D, Lu K, Hatfield-Seung A, Blackford A, **Marr KA**, Treadway S, Ostrander D, Nussenblatt V, Karp J. Epidemiology, outcomes, and risk factors of invasive fungal infections in adult patients with acute myelogenous leukemia after induction. *Diagn Microbiol and Infect Dis* 2013; 75(2): 144-9

113. Flowers CR, Seidenfeld J, Bow EJ, Karten C, Gleason C, Hawley DK, Kuderer NM, Langston AA, **Marr KA**, Rolston KV, Ramsey SD. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. *J Clin Oncol* 2013; 31(6): 794-810.
114. Lyons JL, Roos KL, **Marr KA**, Neumann H, Trivedi JB, Kimbrough DJ, Steiner L, Thakur KT, Harrison DM, Zhang SX. Cerebrospinal fluid (1,3)- $\beta$ -D-glucan detection as an aid for diagnosis of iatrogenic fungal meningitis. *J Clin Microbiol* 51(4): 1285-7.
115. Slifka MK, Hammarlund E, Lewis MW, Poore EA, Hanifin JM, **Marr KA**, Hecox D, Amanna IJ. Antiviral immune response after live yellow fever vaccination of a kidney transplant recipient treated with IVIG. *Transplantation* 2013; 95(9): e59-61.
116. Neofytos D, Treadway S, Ostrander D, Alonso CD, Dierberg KL, Nussenblatt V, Durand CM, Thompson CB, **Marr KA**. Epidemiology, outcomes, and mortality predictors of invasive mold infections among transplant recipients: a 10-year, single-center experience. *Transpl Infect Dis.* 2013 (in press)
117. Dufresne SF, Leblanc RE, Zhang SX, **Marr KA**, Neofytos D. Histoplasmosis and subcutaneous nodules in a kidney transplant recipient: erythema nodosum versus fungal panniculitis. *Transpl Infect Dis.* 2013; 15(2): e58-63.
118. Durand CM, **Marr KA**, Arnold CA, Tang L, Durand DJ, Avery RK, Valsamakis A, Neofytos D. Detection of cytomegalovirus DNA in plasma as an adjunct diagnostic for gastrointestinal tract disease in kidney and liver transplant recipients. *Clin Infect Dis.* 57(11) 1550-9, 2013.
119. Mauskopf J, Chirila C, Graham J, Gersten ID, Leather H, Maziarz RT, Baden LR, Bolanos- Meade J, Brown JM, Walsh TJ, Horowitz MH, Kurtzberg J, **Marr KA**, Wingard JR. Comparative cost-effectiveness analysis of voriconazole and fluconazole for prevention of invasive fungal infection in patients receiving allogeneic hematopoietic cell transplants. *Am J Health Syst Pharm* 2013 70(17): 1518-27.
120. Alonso CD, Dufresne SF, Hanna DB, Labbe AC, Treadway SB, Neofytos D, Belanger S, Huff CA, Laverdiere M, **Marr KA**. Clostridium difficile infection after adult autologous stem cell transplantation: a multicenter study of epidemiology and risk factors. *Biol Blood Marr Transplantation* 2013 19(10): 1502-8
121. Datta K, Rhee P, Byrnes E, Garcia-Effron G, Perlin DS, Staab JF, **Marr KA**. Isavuconazole activity against *Aspergillus lentulus*, *Neosartorya udagawae*, and *Cryptococcus gattii*, emerging fungal pathogens with reduced susceptibility. *J Clin Microbiol* 2013 51(9): 3090-3.
122. Nucci M, **Marr KA**, Vehreschild MJ, et al. Improvement in the outcome of invasive fusariosis in the last decade. *Clin Microbiol Infect* 20 (6): 580-5, 2014
123. Staab JF, Neofytos D, Rhee P, Jimenez-Oritgosa C, Zhang SX, Perlin DS, **Marr KA**. Target enzyme mutations confer differential echinocandin susceptibilities in *Candida kefyr*. *Antimicrob Agents and Chemother* 58(9): 5421-7
124. Dufresne SF, **Marr KA**, Sydnor E, et al. Epidemiology of *Candida kefyr* in patients with hematological malignancies. *J Clin Microbiol* 2014 52(6):1830-7
125. Kauffman CA, Freifeld AG, Andes DR, Baddley JW, Herwaldt L, Walker RC, Alexander BD, Anaissie EJ, Benedict K, Ito JI, Knapp KM, Lyon GM, **Marr KA**, Morrison VA, Park BJ, Patterson TF, Schuster MG, Chiller TM, Pappas PG. Endemic fungal infections in solid organ and hematopoietic cell transplant recipients enrolled in the Transplant-Associated Infection Surveillance Network (TRANSNET) *Transpl Infect Dis.* 2014 Apr;16(2):213-24
126. Chen P, Sun Q, Huang Y, Atta MG, Turban S, Segev DL, **Marr KA**, Naqvi FF, Alachkar N, Kraus ES, Womer KL. Blood dendritic cell levels associated with impaired IL-12 production and T-cell deficiency in patients with kidney disease: implications for post transplant viral infections. *Transpl Int.* 2014 Jun 25. doi: 10.1111/tri.12381.
127. Franco-Parades C, Womack T, Bohmeyer T, Seller B, Hays A, Patel K, Lizarazo J, Lockhart SR,

- Siddiqui W, and **Marr KA**. Management of *Cryptococcus gattii* meningoenophalitis. *Lancet Infect Dis*; 2014; 70945-4
128. Lyons JL, Thakur KT, Lee R, Watkins T, Pardo CA, Carson KA, Markley B, Finkelman MA, **Marr KA**, Roos KL, and Zhang SX. Utility of measuring (1,3) beta-D-glucan in cerebrospinal fluid for the diagnosis of fungal central nervous system infection. *J. Clin Microbiol* 2015; 53(1): 319-22
  129. Chen P, Sun Q, Huang Y, Atta MG, Turban S, Segev DL, **Marr KA**, Naqvi FF, Alachkar N, Kraus ES, and Womer KL. Blood dendritic cell levels associated with impaired IL-12 production and T-cell deficiency in patients with kidney disease: implications for post-transplant viral infections. *Transp Int* 27(10) 1069-76 (2014)
  130. **Marr KA**, Schlamm HT, Herbrecht R, et al. Combination antifungal therapy for invasive aspergillosis: A Randomized Trial. *Annals Intern Med* 2015; 162(2): 81-9
  131. Shoham S, Ostrander D, **Marr K**. Posaconazole liquid suspension in solid organ transplant recipients previously treated with voriconazole. *Transpl Infect Dis* 2015 17(3): 493-6
  132. Neofytos D, Railkar R, Mullane KM, Fredricks DN, Granwehr B, **Marr KA**, Almyroudis NG, Kontoyiannis DP, Maertens J, Fox R, Douglas C, Iannone R, Kauh E and Shire N. Correlation between circulating fungal biomarkers and clinical outcomes in invasive aspergillosis. *PLoS One*. 2015 10(6):e0129022
  133. Neofytos D, Ostrander D, Shoham S, Laverdiere M, Nguyen H, Clark W, Brass L, Lu N, **Marr KA**. Voriconazole therapeutic drug monitoring: results of a prematurely discontinued randomized multicenter trial. *Transpl Infect Dis* 17(6): 831-7 (2015)
  134. Durand CM, **Marr KA**, Ostrander D, Subramanian A, Valsamakis A, Cox A, Neofytos D. False-positive hepatitis C serology after placement of a ventricular assist device. *Transpl Infect Dis* 18(1): 146-9 (2016)
  135. Maertens JA, Raad II, **Marr KA**, Patterson TF, Kontoyiannis DP, Cornely OA, Bow EJ, Rahav G, Neofytos D, Aoun M, Baddley JW, Giladi M, Heinz WJ, Herbrecht R, Hope W, Karthaus M, Lee DG, Lotheolary O, Morrison VA, Oren I, Selleslag D, Shoham S, Thompson GR, Lee M, Maher RM, Schmitt-Hoffman AH, Zeiher B, Ullmann AJ. Isavuconazole vs. voriconazole for primary treatment of invasive mould disease caused by *Aspergillus* and other filamentous fungi (SECURE): a phase 3, randomized-controlled, non-inferiority trial. *Lancet* 20:387 (2016)
  136. Avery RK, Arav-Boger R, **Marr KA**, Kraus E, Shoham S, Lees L, Trollinger B, Shah P, Ambinder R, Neofytos D, Ostrander D, Forman M, Valsamakis A. Outcomes in transplant recipients treated with foscarnet for ganciclovir-resistant or refractory cytomegalovirus infection. *Transplantation* 2016 63(4): 433-42
  137. Lavellee C, Labbe AC, Talbot JD, Alonso CD, **Marr KA**, Cohen S, Laverdiere M, Dufresne SF. Risk factors for the development of *Clostridium difficile* infection in adult allogeneic hematopoietic stem cell transplant recipients: A single-center study in Quebec, Canada. *Transplant Infect Dis*. 2017 19(1)
  138. Avery RK, Lonze BE, Kraus ES, **Marr KA**, Montgomery RA. Severe chronic norovirus diarrheal disease in transplant recipients: clinical features of an under-recognized syndrome. *Transpl Infect Dis* 2017; 19(2)
  139. Elsegeiny W, **Marr KA**, Williamson PR. Immunology of Cryptococcal infections: developing a rational approach to patient therapy. *Front Immunol* 2108; 9(651)
  140. **Marr KA**, Datta K, Mehta S, Ostrander DB, Rock M, Francis J, Feldmesser M. Urine antigen detection as an aid to diagnose invasive aspergillosis. *Clin Infect Dis* 2018; 67(11): 1705-11.
  141. Sundermann JA, Clancy CJ, Pasculle AW, Liu G, Cumbie RB, Driscoll E, Ayres A, Donahue L, Pergam SA, Aboo L, Andes DR, Chandrasekar P, Galdys AL, Hanson KE, **Marr KA**, Mayer J, Mehta S, Morris MI, Perfect J, Revankar SG, Smith B, Swaminathan S, Thompson GR, Varghese M, Vazquez J, Whimbey E, Wingard JR, Nguyen MH. How clean is the linen at my hospital? The Mucorales on unclean linen discovery study of large United States transplant and cancer centers.

Clin Infect Dis. 2018.

142. Bahr NC, Panackal AA, Durkin MM, Smedema ML, Keown W, Davis TE, Raymond- Guillen L, Park YD, **Marr KA**, Fries BC, Williamson PR, Boulware DR, Wheat LJ. Cryptococcal meningitis is a cause for cross-reactivity in cerebrospinal fluid assays for anti-Histoplasma, anti-Coccidioides and anti-Blastomyces antibodies. *Mycoses*. 2018
143. Golden SH, Bass E, Berry S, Biddison LD, Cayea D, Crews D, Desai S, Ghanem KG, Herzke C, Kirk G, Kisuule F, Levine R, **Marr K**, O'Rourke B, Pasricha P, Pears K, Ray S, Durso SC, Hellmann D, Anderson ME. Building leadership capacity for mission execution in a large academic department of medicine. *Am J Med*. 2018
144. **Marr KA**, Sun Y, Spec A, Lu N, et al for the Cryptococcus Infection Network Cohort (CINCH) Study Working Group. A multicenter longitudinal cohort study of cryptococcosis in human immunodeficiency virus-negative people in the United States. *Clin Infect Dis* 2020; 70(2); 252-61
145. **Marr KA**, Rathmell WK, Hawley JH, Guth KD. Empowering ASCI's support of physician-scientists through stronger institutional connections. *J Clin Invest*. 2019; 129(4): 1516-18
146. Halperin Kuhns VL, Sanchez J, Sarver DC, Khalil Z, Rajkumar P, **Marr KA**, Pluznick JL. Characterizing novel olfactory receptors expressed in the renal cortex. *Am J Physiol Renal Physiol* 2019
147. Wright WF, Bejou N, Shields RK, **Marr KA**, McCarty TP, Pappas PG. Amphotericin B induction with voriconazole consolidation as salvage therapy for FKS-associated echinocandin resistance in *Candida glabrata* septic arthritis and osteomyelitis. *Antimicrob Agents Chemother* 2019 63(8); e00512–19
148. Pang L, Zhao X, Dickens BL, Lim JT, Cook AR, Netea MG, Donnelly JP, Herbrecht R, Johnson EM, Maertens JA, Kullberg BJ, Troke PF, **Marr KA**, Chai LYA. Using routine blood parameters to anticipate clinical outcomes in invasive aspergillosis. *Clin Microbiol Infect*. 26(6): 781
149. Traino K, Snow J, Ham L, Summers A, Segala L, Shirazi T, Biassou N, Panackal A, Anjum S, **Marr KA**, Kreisl WC, Bennett JE, Williamson PR. HIV-negative cryptococcal meningoencephalitis results in a persistent frontal-subcortical syndrome. *Sci Rep* 2019 9(1): 18442
150. Munshaw S, Lee SH, Phan PH, **Marr KA**. The influence of human capital and perceived university support on patent applications of biomedical investigators. *J of Technol Transfer* 44(4), 1216–34
151. Durand CM, Capoferri AA, Redd AD, Zahurak M, Rosenblood DIS, Cash A, Avery RK, Bolanos-Meade J, Bollard CM, Bullen CK, Flexner C, Fuchs EJ, Gallant J, Gladstone DE, Gocke CD, Jones RJ, Kasamon YL, Lai J, Levis M, Luznick L, **Marr KA**, McHugh HL, Mehta Steinke S, Pham P, Phlmeyer C, Pratz K, Shoham S, Wagner-Hohnston N, Xu D, Siliciano JD, Quinn TC, Siliciano RF, Ambinder RF. Allogeneic bone marrow transplantation with post-transplant cyclophosphamide for patients with HIV and hematological malignancies: a feasibility study. *Lancet HIV*. 2020 7(9): 558
152. Sundermann AJ, Clancy CJ, Pasculie AW, Liu G, Cumbie RB, Driscoli E, Ayres A, Donahue L, Pergam SA, Abbo L, Andes DR, Chandrasekar P, Gaidys AL, Hanson KE, **Marr KA**, et al. How clean is the linen at my hospital? The Mucorales on unclean linen discovery study of large U.S. transplant and cancer centers. *Clin Infect Dis* 2019; 68(5): 850–53
153. Anjum S, Dean O, Kosa P, Magone MT, King KA, Fitzgibbon E, Kim HJ, Zalewski C, Murphy E, Billioux BJ, Chisholm J, Brewer CC, Krieger C, Elsegeiny W, Scott TL, Want J, Hunsberger S, Bennett JE, Nath A, **Marr KA**, Bielekova B, Wendler D, Hammoud DA, Williamson P. Outcomes in previously healthy cryptococcal meningoencephalitis patients treated with pulse-taper corticosteroids for post-infectious inflammatory syndrome. *Clin Infect Dis* 2020 PMID 33383587
154. **Marr KA**, Platt A, Tornheim JA, Zhang SX, Datta K, Cardozo C, Garcia-Vida C. Aspergillosis complicating severe coronavirus disease. *Emerg Infect Dis* 2021; 27(1): 18-25
155. Avery RK; Motter JD; Jackson KR, Montgomery RA, Massie AB, Kraus ES, **Marr KA**, et al. Quantifying infection risks in incompatible living donor kidney transplant recipients. *Am J Transplant* 2021; 21(4): 1564-76

156. Avery RK, Chiang TP, **Marr KA**, et al. Inpatient COVID-19 outcomes in solid organ transplant recipients compared to non-solid organ transplant patients: A retrospective cohort. *Am J Transplant* 2021; 21(7): 2498-2508
157. Sun Y, McCulloch CE, **Marr KA**, Huang CY. Recurrent event analysis with data collected at informative clinical visits in electronic health records. *J Am Stat Assoc.* 2021; 116(534): 594-604
158. Permpalung N, Chiang TP, Massie AB, Zhang SX, Avery RK, Nematollahi S, Ostrander D, Segev DL, Marr KA. COVID-19 associated pulmonary aspergillosis in mechanically ventilated patients. *Clin Infect Dis* 2021; doi: 10.1093
159. Mercier T, Castagnola E, **Marr KA**, Wheat LJ, Verweij PE, Maertens JA. Defining galactomannan positivity in the updated EORTC/MSGERC consensus definitions of invasive fungal diseases. *Clin Infect Dis* 2021; 72(Supp 2): S89-94
160. Dean O, Anjum S, Scott T, Ham L, Traino K, Wang J, Hunsberger S, Powers JH, **Marr KA**, Snow J, Williamson PR. Quality of life of HIV-negative, previously healthy individuals following cryptococcal meningoenzephalitis. *Sci Rep* 2021; 11 (1): 3673. PMID: 33574462
161. Wingard JR, Alexander BD, Baden LR, Chen M, Sugrue MW, Leather HL, Caliendo AM, Clancy CJ, Denning DW, Marty FM, Nguyen MH, Wheat LJ, Logan BR, Horowitz MM, **Marr KA**. Impact of Changes of the 2020 Consensus Definitions of Invasive Aspergillosis on Clinical Trial Design: Unintended Consequences for Prevention Trials? *Open Forum Infect Dis* 2020; 8(10). PMID 34631917
162. Cihakova D, Streiff MB, Menez SP, Chen TK, Gilotra NA, Michos ED, **Marr KA**, Karaba AH, Robinson ML, Blair PW, Dioverti MV, Post WS, Cox AL, Antar AA. High-value laboratory testing for hospitalized COVID-19 patients: a review. *Future Virology.* 2021 PMID 34567235
163. Nematollahi S, Permpalung N, Zhang SX, Morales M, **Marr KA**. *Aspergillus lentulus*: an under-recognized cause of antifungal drug-resistant aspergillosis. *Open Forum Infect Dis.* 2021. PMID 34466628
164. Sait AS, Chiang TP, **Marr KA**, et al. Outcomes of SOT recipients with Covid-19 in different eras of Covid-19 therapeutics. *Transplant Direct.* 2021 PMID: 34966840
165. Yang DH, England MR, Salvator H, Anjum S, Park YD, **Marr KA**, et al. *Cryptococcus gattii* species complex as an opportunistic pathogen: underlying medical conditions associated with the infection. *mBio* 2021 PMID: 34700378
166. Datta K, LaRue R, Permpalung N, Das S, Zhang S, Mehta Steincke S, Buskin Y, Nosanchuk JD, **Marr KA**. Development of an Interferon-gamma release assay (IGRA) to Aid Diagnosis of histoplasmosis. *J Clin Microbiol* 2022 PMID 36190260
167. Ssebambuilidde K, Anjum SH, Hargarten JC, Chittiboina P, Shoham S, Seyedmousavi S, **Marr KA**, Hammoud DA, Billieux BJ, Williamson PR. Treatment recommendations for non-HIV associated cryptococcal meningoenzephalitis including management of post-infectious inflammatory response syndrome. *Front Neurol.* 2022 PMID 36530631
168. Permpalung N, Liang T, Gopinath S, Bazemore K, Mathew J, Ostrander D, Durand CM, Shoham S, Zhang SC, **Marr KA**, Avery RK, Shah PD. Invasive fungal infections after respiratory viral infections in lung transplant recipients are associated with lung allograft failure and chronic lung allograft dysfunction within 1 year. *J Heart Lung Transplant.* 2023 PMID 36925381
169. Permpalung N, Bazemore K, Mathew J, Barker J, Horn S, Miller S, Cochran W, Garneau WM, Gopinath S, Ostrander D, Avery RK, Shoham S, Zhang SX, Agbor-Enoh S, **Marr KA**, Shah PD. Secondary bacterial and fungal pneumonia complicating SARS-CoV-2 and Influenza infections in lung transplant recipients. *J Heart Lung Transplant.* 2022 PMID: PMC8988613
170. Permpalung N, Chiang TPY, Avery RK, Ostrander D, Datta K, Segev DL, Durand CM, Zhang SX, Massie AB, and **Marr KA**. Coronavirus disease 2019-Associated pulmonary aspergillosis: A noninvasive screening model for additional diagnostics. *Open Forum Infect Dis.* 2023 10(4) PMID PMC10077830 PMID:37938782

171. Maji A, Soutar CP, Zhang J, Lewandowska A, Uno BE, Yan S, Murhade G, Nimerovsky E, Borcik CG, Arango AS, Lange JD, Marin-Toledo JP, Lyu Y, Bailey KL, Roady PJ, Holler JT, Khandelwal A, SantaMaria AM, Sanchez H, Juvvadi PR, Johns G, Hageman MJ, Krise J, Gebremariam T, Youssef EG, Bartizal K, **Marr KA**, Steinbach WJ, Ibrahim AS, Patterson TF, Widerhold NP, Andes DR, Pogorelov TV, Schwieters CD, Fan TM, Rienstra CM, Burkh MD. Tuning sterol extraction kinetics yields a renal-sparing polyene antifungal. *Nature* 2023
172. Anjum SH, Bennett JE, Dean O, **Marr KA**, Hammoud DA, Williamson PR. Neuroimaging of Cryptococcal meningitis without Human Immunodeficiency Virus: Data from a Multi-Center cohort study. *J Fungi*. 2023. PMID: 37233305
173. Permpalung N, Chiang TP, Manothummetha K, Ostrander D, Datta K, Segev DL, Durand CM, Mostafa HH, Zhang SX, Massie AB, **Marr KA**, Avery RK. Invasive fungal infections in inpatient solid organ transplant recipients with COVID-19: A multicenter retrospective cohort. *Transplantation* 2024 PMID 38419156

### Invited review articles

1. **Marr KA**, Schwab S, Sexton D. Treatment of infections of central venous catheters used for hemodialysis. 1996; *Up-to-Date in Infectious Diseases and Nephrology*.
2. **Marr KA**, Bowden RA. Fungal infections in patients undergoing blood and marrow transplantation. *Transpl Infect Dis*. 1999; 1:237-246.
3. **Marr KA**. The changing spectrum of candidemia in oncology patients: therapeutic implications. *Curr Opin Infect Dis*. 2000; 13(6):615-620.
4. **Marr KA**. Rationale for selection of antifungals for prevention in hematopoietic stem cell transplant recipients. *Oncology*; 2000 10 (Supp):1-5.
5. **Marr KA**. *Staphylococcus aureus* bacteremia in hemodialysis patients. *Seminars in Dialysis*. 2000; 13(1): 23-29.
6. **Marr KA**. Prevention of fungal infections after hematopoietic stem cell transplantation. *Blood and Marrow Transplant Rev*. 2001; 11(1): 4-7.
7. **Marr KA**. Antifungal prophylaxis in HSCT recipients. *Curr Opin Infect Dis*. 2001; 14:423-26.
8. **Marr KA**, M Boeckh. Commentary on "Prophylaxis against deep fungal infections and CMV end organ disease in bone marrow transplant recipients: a review" (A. Wilkin and J. Feinberg), *Oncology*. 2001; 14(12): 1712.
9. **Marr KA**. Fungal infections in hematopoietic stem cell transplant recipients. *Curr Treatment Options Infect Dis*. 2001; 3:533-41.
10. **Marr KA**. Fungal disease of the lung. *Respiratory Care*. 2001; 46(6): 623.
11. **Marr KA**, Patterson T, Denning D. Aspergillosis. *Infect Dis Clin N Amer*. 2002 ; 16(4): 875-94.
12. Junghanss C, **Marr KA**. Infectious risks and outcomes after stem cell transplantation: are non-myeloablative transplants changing the picture? *Curr Opin Infect Dis*. 2002; 15(4):347-53.
13. **Marr KA** (ed.). *Curr Opin Infect Dis*. 2003; 16-6.
14. **Marr KA**. New approaches to invasive fungal infections *Curr Opin Hematol* 2003; 445-450.
15. **Marr KA**. Issues in the design of antifungal prophylaxis trials in hematopoietic stem cell transplant recipients. *Clin Infect Dis*. 2004; 39:S4 .
16. **Marr KA**. Antifungal therapy for febrile neutropenia: Issues in clinical trial design. *Curr Opin Invest Drugs*. 2004, 5: 202-207
17. **Marr KA**. Combination antifungal therapy: where are we now, and where are we going? *Oncology (Suppl.)*. 2004; 18(13): S24-29.

18. Panackal A, Marr KA. *Scedosporium/Pseudallescheria* Infections. *Sem Resp Crit Care.* 2004; 25(2): 171-81.
19. M Nucci, **KA Marr.** Emerging fungal diseases. *Clin Infect Dis.* 2005; 41(4):521-6.
20. **Marr KA,** Leisenring W. Design issues in studies evaluating diagnostic tests for aspergillosis. *Clin Infect Dis.* 2005; 41suppl 6. S381-6.
21. Balajee SA, Marr KA. Phenotypic and genotypic identification of pathogenic *Aspergillus* species. *Future Microbiol.* 2006; 1(4): 435-45.
22. Barnes P, Marr KA. Aspergillosis: spectrum of disease, diagnosis, and treatment. *Infect Dis Clin N Amer.* 2006 ; 20(3): 545-61.
23. Upton A, Marr KA. Emergence of opportunistic mould infections in hematopoietic stem cell transplant recipients. *Curr Infect Dis Reports.* 2006; 8: 434-441.
24. **Marr KA.** Fungal infections in stem cell transplant recipients. *Med Mycol.* 2008; 46(4): 293-302.
25. **Marr KA.** Primary antifungal prophylaxis in hematopoietic stem cell transplant recipients: clinical implications of recent studies. *Curr Opin Infect Dis* 2008; 21(4): 409-14.
26. **Marr KA.** Fungal infections in oncology patients: Update on Epidemiology, Prevention, and Treatment. *Curr Opin Oncology* 2010 22(2): 138-42
27. **Marr KA,** Bow E, Chiller T, Maschmeyer G, Ribaud P, Segal B, Steinbach W, Wingard JR, Nucci M. Fungal infection prevention after hematopoietic cell transplantation. *Bone Marrow Transplant* 2009 44(8): 483-7
28. Byrnes EJ, Marr KA. The outbreak of *Cryptococcus gattii* in Western North America: Epidemiology and Clinical Issues. *Curr Infect Dis Rep.* 2011 13(3): 256-61.
29. Chaudhary N and Marr KA. Impact of *Aspergillus fumigatus* in allergic airway diseases. *Clinical and Translational Allergy* (2011)
30. Shoham S and **Marr KA.** Invasive fungal infections in solid organ transplant recipients. *Future Medicine* 2012; 7(5): 639-55.
31. **Marr KA.** *Cryptococcus gattii* as an important fungal pathogen in western North America. *Exp Rev Anti Infect Ther* 2012; 10(6): 637-43.
32. **Marr KA.** Delayed opportunistic infections in hematopoietic stem cell transplantation patients: a surmountable challenge. *Hematology Am Soc Hematol Educ Program* 2012; 265-70
33. Alonso CD and Marr KA. Clostridium difficile infection among hematopoietic stem cell transplant recipients: beyond colitis. *Curr Opin Infect Dis* 2013; 26(4): 326-331
34. **Marr KA.** The ownership paradox: nurturing continuity and change for the future ASCI. *J Clin Invest.* 2019 129(12): 5055-61

### Case Reports

1. **Marr KA,** Hirschmann JV, Thorning D, GJ Raugi. Protothecosis. *Clin Infect Dis.* 1998; 26:756-7.
2. Ustun C, Huls G, Stewart M, **Marr KA.** Resistant *Microascus cirrosus* pneumonia can be treated with a combination of surgery, multiple anti-fungal agents and a growth factor. *Mycopathologia.* 2006 162(4):299-302.
3. Durand CM, Alonso CD, Subhawong AP, Kwiatkowski NP, Showel M, Carroll KC, **Marr KA.** Rapidly progressive cutaneous Rhizopus microspores infection presenting as Fournier's gangrene in a patient with acute myelogenous leukemia. *Transplant Infect Dis* 2011: 1398-2273
4. Garrett L, **Marr KA,** West S, and Allada G. 74 yr old man from the Pacific Northwest with fever and a lung mass. *Chest.* 2011. 140(3): 814-7.
5. Sundi D, Tseng K, Mullins JK, **Marr KA,** Hyndman ME. Invasive fungal bezoar requiring partial cystectomy. *Urology* 2012; 79(2): e21-2.

6. Meriden Z, **Marr KA**, Lederman HM, Illei PB, Villa K, Riedel S, Carroll KC, Zhang SX. *Ochroconis gallopava* infection in a patient with chronic granulomatous disease: case report and review of the literature. *Med Mycol* 2012 (in press).
7. Neofytos D, Shoham S, Dierberg K, Le K, Dufresne S, Zhang SX, **Marr KA**. Diagnostic and therapeutic challenges in a liver transplant recipient with central nervous system invasive aspergillosis. *Diagn Microbiol Infect Dis* 2012; 73(4): 374-5.
8. Atamna A, Yeshurun M, Shargian L, Raanani P, Kramer M, Ben Zvi H, Ben Ami R, Marr KA, Bishara J. Fatal invasive pulmonary and cerebral aspergillosis due to triazole-resistant *Aspergillus fumigatus* with multiple CYP51A mutations. *J Antimicrob Chemother* 2024 PMID 38334380

### Guidelines and Consensus Statements

1. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, **Marr KA**, Morrison VA, Segal BH, Steinbach WJ, Stevens DA, van Burik J, Wingard JR, Patterson TF. Treatment of Aspergillosis: Clinical practice guidelines of the Infectious Diseases Society of America. *Clin Infect Dis* 2008; 46(3): 327- 360.
2. De Pauw B, Walsh TJ, Donnelly JP, Stevens D, Edwards J, Calandra T, Pappas P, Maertens J, Lorthalary O, Kauffman C, Denning D, Patterson T, Maschmeyer G, Bille J, Dismukes B, Herbrecht R, Hope W, Kibbler C, Kullberg BJ, **Marr KA**, Perfect J, Restrepo A, Ruhnke M, Segal B, Sobel J, Sorrell TC, Viscoli C, Wingard J, Zaoutis T, Bennett JE. Revised definitions of the EORTC/MSG Consensus group for invasive fungal diseases. *Clin Infect Dis*. 2008; 46(12): 1813-21.
3. Limper AH, Knox KS, Sarosi GA, Ampel NM, Bennett JE, Catanzaro A, Davies SF, Dismukes WE, Hage CA, **Marr KA**, Mody CH, Perfect JR, Stevens DA; American Thoracic Society Fungal Working Group. An official American thoracic society statement: treatment of fungal infections in adult pulmonary and critical care patients. *Am J Respir Crit Care Med* 2011; 183(1): 96-128.
4. Flowers CR, Seidenfeld J, Bow EJ, Karten C, Gleason C, Hawley DK, Kuderer NM, Langston AA, **Marr KA**, Rolston KV, Ramsey SD. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. *J Clin Oncol* 2013; 31(6): 794-810.
5. Pappas PG, Kauffman CA, Andes DR, Clancy CJ, **Marr KA**, Ostrosky-Zeichner L, Reboli AC, Schuster MG, Vazquez JA, Walsh TJ, Sobel JD. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. *Clin Infect Dis* 15; 62(4): e1-50 (2016)
6. Pappas PG, Kauffman CA, Andes DR, Clancy CJ, **Marr KA**, Ostrosky-Zeichner L, Reboli AC, Schuster MG, Vazquez JA, Walsh TJ, Sobel JD. Executive Summary: Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. *15(62):4*: 409-17
7. Patterson TF, Thompson GR, Denning DW, Fishman JA, Hadley S, Herbrecht R, Kontoyiannis DP, **Marr KA**, Morrison VA, Nguyen MH, Segal BH, Steinbach WJ, Stevens DA, Walsh TJ, Wingard JR, Young JA, Bennett JE. Executive Summary: Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. *Clin Infect Dis* 63(4): 4-42
8. Donnelly JP, Chen SC, Kauffman CA, Steinbach WJ, Baddley JW, Verweij PE, Clancy CJ, Wingard JR, Lockhart SR, Groll AH, Sorrell TC, Bassetti M, Akan H, Alexander BD, Andes D, Azoulay E, Bialek R, Bradsher RW, Bretagne S, Calandra T, Caliendo AM, Castagnola E, Cruciani M, Cuenca-Estrella M, Decker CF, Desai SR, Fisher B, Harrison T, Heussel CP, Jensen HE, Kibbler CC, Kontoyiannis DP, Kullberg BJ, Lagrou K, Lamothe F, Lehrnbecher T, Loeffler J, Lorthalary O, Maertens J, Marchetti O, **Marr KA**, Masur H, Meis JF, Morrissey CO, Nucci M, Ostrosky-Zeichner L, Pagano L, Patterson TF, Perfect JR, Racil Z, Roilides E, Ruhnke M, Prokop



- CS, Shoham S, Slavin MA, Stevens DA, Thompson GR, Vazquez JA, Viscoli C, Walsh TJ, Warris A, Wheat LJ, White PL, Zaoutis TE, Pappas PG. Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. *Clin Infect Dis* 2020 71(6): 1367-76
9. Yasinskaya Y, Bala S, Waack U, Dixon C, Higgins K, Moore JN, Jjingo CJ, O'Shaughnessy E, Colangelo P, Botgros R, Nambiar S, Angulo D, Dane A, Chiller T, Hodges MR, Sandison T, Hope W, Walsh TJ, Pappas P, Watragkou A, Kovanda L, Rex JH, **Marr KA**, Ostrosky-Zeichner L, Sekine S, Deshpande M, Shukla SJ, Farley J. Food and Drug Administration Public Workshop Summary – Development Consideration of Antifungal Drugs to Address Unmet Need. *Clin Infect Dis* 2023 PMID 37021650
  10. Jhingo CJ, Bala S, Waack U, Needles M, Bensman TJ, McMaster O, Smith T, Blakely B, Chan IZ, Puthawala K, Dixon C, Kim Y, Lim R, Colangelo P, St. Clair C, Nambiar S, Moss RB, Botgros R, Bazaz R, Denning DW, Marr KA, Husain S, Berman L, Christensen DJ, Keyword C, Clayton RG, Walsh TJ, Song HSE, Shukla SJ, Farley J. Food and Drug Administration Public Workshop Summary – Inhaled Antimicrobials. *Clin Infect Dis* 2024 PMID: 37802928

### Editorials

1. **Marr KA**. Editorial commentary: Empirical antifungal therapy: new options, new trade-offs. *New Eng J Med*. 2002; 346(4): 278-80.
2. Ostrosky-Zeichner L, **Marr KA**, Rex JH, Cohen SH. Amphotericin B: time for a new gold standard. *Clin Infect Dis*. 2003; 37:415-425.
3. **Marr KA**. Editorial commentary: *Aspergillus* galactomannan: A surrogate endpoint to assess outcome of therapy? *Clin Infect Dis*. 2008; 46(9): 1423-5.
4. Kontoyiannis DP, Lewis RE, **Marr K**. The burden of bacterial and viral infections in hematopoietic stem cell transplant. *Biol Blood and Marr Transp* 2009 15(1): 128-33.
5. **Marr KA**. Editorial commentary: *Cryptococcus gattii*: the tip of the iceberg. *Clin Infect Dis* 2011. 53(12): 1196-8
6. Shoham S and **Marr KA**. Treatment of iatrogenic fungal infections: A black mold defines a new gray-zone in medicine. *Annals Intern Med*. 2012
7. Spellberg B, **Marr KA**, Brass EP. Regulatory pathways for new antimicrobial agents: trade-offs to keep the perfect from being the enemy of the good. *Clin Pharmacol Ther* 2016; 100(6): 597-99
8. Permpalung, N, Maertens J, **Marr KA**. Diagnostic dilemma in Covid-19 associated pulmonary aspergillosis. *Lancet Infect Dis*. 2021 PMID: 33662327

### Letters, correspondence

1. **Marr KA**, Boeckh M. Risk-stratified approach to antifungal prophylaxis. *Clin Infect Dis*. 2001; 32(2).
2. Boeckh M, Nichols WG, **Marr KA**. Long term care after HSCT in adults. *New Eng J Med*. 2003 14;347(20):1625-6.
3. **Marr KA**, Boeckh M. Prevention of aspergillosis. *Blood*. 2004; 104(5): 1582.
4. **Marr KA**. Book Review: Antibiotics and Chemotherapy. 2004; Mycopathologia.
5. Staab J, **Marr KA**. Aspfl6 is not an *Aspergillus fumigatus* allergen (letter). *Med Mycol*. 2008.
6. **Marr KA**, Leisenring W, Bow E. Empirical vs. pre-emptive antifungal therapy. *Clin Infect Dis* 2009 49(7): 1138-9.
7. **Marr KA**, Datta K, Pirofski LA, Barnes R. *Cryptococcus gattii* infection in healthy hosts: a sentinel for subclinical immunodeficiency? *Clin Infect Dis*. 2012. 54(1): 153-4.

8. Panackal AA, **Marr KA**, Williamson PR. Dexamethasone in cryptococcal meningitis. *N Eng J Med* 2016 375(2): 188
9. Permpalung N, Maertens J, **Marr KA**. Diagnostic dilemma in COVID-19-associated pulmonary aspergillosis. *Lancet Infect Dis* 2021; 21(6): 766-67
10. Avery RK, Chiang TP, **Marr KA**, Garonzik-Wang J, Segev DL, Massie AB. Response to “COVID-19 in SOT vs. non-SOT.” *Am J Transplant* 2021; 21(6): 2306

### **Book chapters, monographs**

1. **Marr KA**, Bowden RA. New lung infiltrates in hematopoietic stem cell transplant recipients. In *Infectious Diseases*. Armstrong D, Cohen J (ed.). Mosby International 1999, Vol. 1, Section 4, pp. 9.4-9.8
2. **Marr KA**, Walsh TJ. Management strategies for infections caused by *Candida* species. In *Management of Infection in Oncology Patients*, Wingard J, Bowden RA (ed.) Martin Dunitz 2003 pp. 165-178.
3. Walsh TJ, **Marr KA**. Invasive aspergillosis complicating neoplastic diseases and hematopoietic stem cell transplantation. In *Management of Infection in Oncology Patients*,. Wingard J, Bowden RA (ed.) Martin Dunitz 2003 pp. 179-202.
4. Boeckh M, **Marr KA**. Infections in hematopoietic stem cell transplantation. In: *Clinical Approach to Infection in the compromised Host* (chapter 17). 4<sup>th</sup> Edition. Eds. Rubin, R. and Young, L.S. Plenum Medical Book Company, New York. 2002 pp. 527-571.
5. **Marr KA**. Fungal infections in blood and marrow transplant recipients. In: *Clinical Mycology*. 2003 Oxford University Press, Eds WE Dismukes, PG Pappas and JD Sobel.
6. **Marr KA**. Infections in stem cell transplant recipients. In *Infectious Diseases* (2<sup>nd</sup> edition). Cohen J, Powderly WG (ed.). Mosby International 2003.
7. SteinbachWJ, **Marr KA**. Mould infections after stem cell transplantation. In *Transplant Infections* (2<sup>nd</sup> edition). Bowden RA, Ljungman P, Paya CV (ed.). Lippincott Williams & Wilkins. 2003.
8. **Marr KA**. Fungal infections after hematopoietic stem cell transplantation. In *Infectious Diseases*. Armstrong D, Cohen (ed.). Mosby International. Vol. 2. 2003
9. **Marr KA**. New antifungal therapies. In *Year in Infections* 2003.
10. **Marr KA**. Fungal infections in blood and marrow transplant recipients. *Infections in Immunocompromised Hosts*. Wingard J, Anaissie E (ed.). Marcel Dekker Inc. 2005.
11. Imhof A, **Marr KA**. Echinocandins. *Antimicrobial Therapy and Vaccines*. Yu V. (ed.). Lippincott, Williams and Wilkins. 2004. Vol. 2: 423-436.
12. **Marr KA**. Fungal Infections in Blood and Marrow Transplant Recipients. In: Wingard JR, Anaissie EJ (eds). *Fungal Infections in the Immunocompromised Patient*. Boca Raton, FL: Taylor & Francis Group 2005:75-95.
13. **Marr KA**. Approach to fever and suspected infection in the compromised host. *Cecil Textbook of Medicine*. Goldman and Shafer (ed.) 24<sup>th</sup> ed. 2008
14. **Marr KA**. Treatment of Invasive Pulmonary Aspergillosis. A.C. Pasqualotto (ed.). *Aspergillosis: from Diagnosis to Prevention*. Springer Science and Business Media 2009
15. Neofytos D and **Marr KA**. Fungal infections in Stem Cell Transplant Recipients. In: *Clinical Mycology*. Oxford University Press, Eds WE Dismukes, PG Pappas and JD Sobel. 2009
16. Neofytos D and Marr KA. Diagnosis of fungal infections. In: *Management of Infections in Cancer Patients*. Ed. A Safdar 2013
17. SteinbachWJ, **Marr KA**. Mould infections after stem cell transplantation. In *Transplant Infections* (3<sup>rd</sup> edition). Bowden RA, Ljungman P, Paya CV (ed.). Lippincott Williams & Wilkins. 2009.

18. Bartlett K, Byrnes E, Duncan C, Fyfe M, Galanis E, Heitman J, Hoang L, Kidd S, Maccougall L, Mak S, **Marr KA**, Morshed M, West S, and J Kronstad. The emergence of *Cryptococcus gattii* infections on Vancouver Island and expansion in the Pacific Northwest. In *Cryptococcus. From Human pathogen to model yeast*. Heitman, Kozel, Kwong-Chung, Perfect and Casadevall (ed). ASM Press. 2011.
19. Sorrell TC, Chen SCA, Phillips P, and **KA Marr**. Clinical perspectives on *Cryptococcus neoformans* and *Cryptococcus gattii*: implications for diagnosis and management. In *Cryptococcus. From Human pathogen to model yeast*. Heitman, Kozel, Kwong-Chung, Perfect and Casadevall (ed). ASM Press. 2011.
20. Spellberg B, **Marr KA**, Filler SG. *Candida: What should clinicians and scientists be talking about?* In *Candida and Candidiasis, 2<sup>nd</sup> Edition*. Calderone and Clancy (ed) ASM Press 2012
21. **Marr KA**. Approach to fever and suspected infection in the compromised host. *Cecil Textbook of Medicine*. Goldman and Shafer (ed.) 25<sup>th</sup> ed. 2013
22. **Marr KA**. Fungal infections after hematopoietic cell transplantation. *Thomas' Hematopoietic Cell Transplantation*. Forman, Negrin, Antin, Appelbaum (ed). Wiley Blackwell 2016

#### **Books, textbooks (ed.)**

1. Maertens J, **Marr KA** (Ed.) *Diagnosis of Fungal Infections*. Marcel Dekker, Inc. Publishers, NY (2007)
2. Section editor, *Infectious Diseases (3<sup>rd</sup> edition)*. Cohen, Powderly (Ed.). Mosby Publishers(2010)
3. **Marr KA** and Subramanian A (Ed). *Transplant and Oncology Infectious Diseases*. *Infectious Disease Clinics of North America* 24(2)(2010).
4. Section editor, *Infectious Diseases (4<sup>th</sup> edition)*. Cohen, Powderly, Opal (Ed.). Mosby Publishers (2016)

#### **Business, Technology Transfer Research**

1. Munshaw S, Lee SH, Phan PH, **Marr KA**. The influence of human capital and perceived university support on patent applications of biomedical investigators. *J of Technol Transfer* 44(4), 1216 – 34
2. **Marr KA**, Phan PH. The valorization of nonpatent intellectual property in academic medical centers. *J Technol Transfer* 45(6): 1823-41 (2020)

#### **Other media**

- |           |   |
|-----------|---|
| 2001      | CME Teleconference series: “The changing face of fungal infections”   |
| 2002      | Up to Date in Infectious Diseases (Section Editor)  |
| 2003      | Television: Discovery Health Network Series: “Internal Infections, Hidden Dangers” (finalist in 20 <sup>th</sup> International Television Science Programme Festival) |
| 2003      | Television: Co-host for Discovery Channel / PBS Special on Infections   |
| 2007      | Television: Co-host for Information TV, Public Broadcast System   |
| 2008–2010 | eLiterature Review: eTransplant ID review (Program Director)  |
| 2011      | Contributing author, <i>Clinical Decision Support in Hematology, Infectious Diseases, and Pulmonary Medicine</i>  |
| 2011      | Medscape CME/CE video Lecture: Invasive Candidiasis: The Challenge of Diagnosis   |
| 2012      | Immunocompromised host and opportunistic infections: IDCareLive Congress  |
| 2013      | Interview, Internet Radio and Webcast, “The Coaching Show”  |

2013	Interview, Fungi on the March, Scientific American Magazine, Nov. 2013
2021	Interview, Scientific American Magazine, April 2021
2021	Interview, Forbes Magazine, (au. Judy Stone)
2021	Speaker, COVID-19 Clinical Forum (remote) interview, Wall Street Journal

## EXTRAMURAL FUNDING

### Previous

1998 – 2004	Azole-resistant <i>Candida</i> in marrow transplant patients K08 AI01571 NIH / NIAID \$600,000 Principal investigator: Marr
1999 – 2001	Antifungal drug resistant <i>Aspergillus</i> American Lung Association Research Grant Total direct \$50,000 Principal investigator: Marr
2000	Lymphocyte Mediated Immunity Against <i>Aspergillus</i> NIH PILOT TE3161 \$30,000 Principal investigator: Marr
2001 – 2003	Caspofungin in combination with cyclosporine: safety analyses Merck research study Principal investigator: Marr, FHCRC
2001 - 2006	Adult Leukemia Research Center, Project 5. Infectious Complications CA18029 NIH / NCI \$186,897 Principal investigator: Appelbaum Marr investigator, 2001-2006
2003 – 2005	Antifungal drug resistance in <i>Aspergillus</i> R21 AI05592 NIH / NIAID \$300,000 Principal investigator: Marr
2004 – 2008	Quantitative PCR for the Detection of Fungal Infections R01 AI054703 NIH / NIAID \$600,000 Principal investigator: Fredricks, Marr investigator
2005 – 2007	Galactomannan vs. glucan assays for diagnosis of invasive aspergillosis Associates of Cape Cod \$60,000 Principal investigator: Marr

2008                    *Cryptococcus gattii* in the Northwest  
 Enzon Research Grant  
 \$18,000  
 Principal investigator: Marr

2003 – 2009            Inflammatory responses to *Aspergillus fumigatus*  
 R01 AI51468  
 NIH / NIAID  
 \$875,000  
 Principal Investigator: Marr; % effort: 10

2003 – 2009            Bio Rad Galactomannan ELA for Diagnosis of Aspergillosis  
 U01 AI54736  
 NIH / NIAID  
 \$1,972,457  
 Principal investigator: Marr; % effort: 15

2005 – 2008            Genetic diversity of *Aspergillus fumigatus*  
 R21 AI067971  
 NIH / NIAID  
 \$275,000  
 Principal investigator: Marr; % effort: 5

2005 - 2010            Immune reconstitution to *Aspergillus*  
 R01 AI67710  
 NIH / NIAID  
 \$1,125,000  
 Principal Investigator: Marr; % effort: 10

2007 – 2009            Effect of CFTR mutation on innate immune response to *A. fumigatus*  
 Cystic Fibrosis Foundation Research Grant  
 Total direct: 166,666  
 Principal investigator: Marr

2009 - 2011            Administration of intravenous voriconazole in patients with renal impairment  
 Pfizer Investigator-initiated research grant  
 \$95,000  
 Principal investigator: Marr

2010 - 2011            A study to evaluate in vivo significance of variable echinocandin susceptibility and  
 relative prevalence of *A. lentulus*  
 Astellas Pharmaceuticals Research Grant  
 \$54,386  
 Principal investigator: Marr

2008 – 2011            Decreased susceptibility of the newly described *Aspergillus lentulus*  
 Merck Research Grant  
 \$38,471  
 Principal investigator: Marr

2011 – 2012            Improving the diagnosis of histoplasmosis in an endemic region  
 NIH R56 AI 095048  
 \$246,178  
 Principal investigators: Page / Marr

2011 – 2013	Candida albicans Adhesion and Candidiasis NIH R21DE021972 \$451,000 Principal investigator: Staab
2011 – 2012	Epidemiology and Mechanism of Echinocandin Resistance in Candida kefyr Merck Research Grant \$33,465 Principal investigator: Marr
2011 – 2012	Evaluation of in vitro Susceptibilities of Isavuconazole and other azoles in clinical isolates of Aspergillus lentulus and Cryptococcus gattii Astellas Research Grant \$52,066 Principal investigator: Marr
2011 – 2012	Prospective, natural history study of Cryptococcus gattii infections in the United States Sigma-Tau Pharmaceuticals Research Grant \$25,000 Principal investigator: Marr
2010-2011	Development of a Point-of-Care Diagnostic Device for Aspergillosis JHU ICTR – Accelerated Translational Incubator Pilot \$92,970 Principal investigator: Staab (Marr mentor)
2013 -2014	Point of care Lateral flow diagnostic assay for fungal infections TEDCO Maryland Innovation Initiative Phase I \$100,000 Principal investigators: Marr
2015	Diagnostics for latent histoplasmosis Fisher Center Discovery Program \$49,860 Principal investigator: Marr
2010 - 2015	Patient oriented research in Transplant and Oncology ID NIH K24AI05118 \$1,052,925 Principal investigator: Marr
2015 - 2016	Urine Diagnostics for Invasive Aspergillosis NIH R41AI115866 \$149,962 Principal investigator: Marr
2015 -2016	Point of care Lateral flow diagnostic assay for fungal infections TEDCO Maryland Innovation Initiative Phase II \$25,000 Principal investigators: Shallcross (MycoMed Technologies)/Marr (JHU)
2013 - 2017	Prospective cohort study of cryptococcosis. NIH U01AI109657

	\$1,944,101 Principal investigators: Kieren Marr, Peter Williamson
2017 – 2018	Assessing cumulative morbidity of CMV after BMT Merck medical research grant \$200,000 Principal investigator: Kieren Marr
2017 – 2019	Urine diagnostics for aspergillosis NIH R42AI115866 \$ 1,859,693 Principal investigator: Marr
2019 – 2020	CMV Associated Outcomes in Renal Transplant Merck Research Contract Total direct \$223,612.30 Principal investigator: Marr
2021 – 2023	Urine Diagnostics for Pulmonary Aspergillosis Cystic Fibrosis Foundation Infection Research Award IPN20086223 \$500,000 Principal Investigator: Marr KA
2021 – 2022	Urine Diagnostics for Aspergillosis R44AI157572-01 (MycoMed Technologies) \$976,576 Principal Investigator: Marr KA

### **Extramural Funding Research Grants – Clinical Trials (only 2007 - 2013)**

#### Completed

Principal Investigator: Marr, Kieren      ViroPharma 1263-301      Period: 6/26/07-8/30/08  
A Randomized, Double-Blind Study To Assess The Efficacy And Safety Of Prophylactic Use Of Maribavir Versus Oral Ganciclovir For The Prevention Of Cytomegalovirus Disease In Recipients Of Orthotopic Liver Transplants

Principal Investigator: Marr, Kieren      UCLA NCT419770      Period: 7/5/07-8/30/08  
The Deferasirox (Exjade)-Ambisome Therapy (DEFEAT) for Mucormycosis Study

Global principal Investigator: Marr, Kieren      Pfizer A8851009      Period: 3/24/08–12/31/11  
A Prospective, Randomized Trial Comparing the Efficacy of Anidulafungin and Voriconazole in Combination to that of Voriconazole Alone When Used for Primary Therapy of Proven or Probable Invasive Aspergillosis

Principal Investigator: Subramanian, Aruna      Chimerix CMX001      Period: 9/5/08-9/13/10  
A Multicenter, Randomized, Double-Blind, Placebo controlled, Multiple Dose Study Of The Safety, Tolerability And Population Pharmacokinetics Of Cmx001 In Posttransplant Subjects With Bk Virus Viruria

Principal Investigator: Marr, Kieren      ADMA Biologics 001      Period: 11/19/08-5/15/10

A multicenter, double-blind, randomized, placebo-controlled, dose-ranging trial evaluating the safety and efficacy of RI-001 in medically immunosuppressed Respiratory Syncytial Virus (RSV) infected patients at risk of lower tract RSV illness

Principal Investigator: Marr, Kieren Merck MK-0000-089 Period: 7/01/09-6/30/13  
A Prospective, Non-Intervention, Observational Assessment of the Correlation Between Circulating Biomarkers of Fungal Bioburden and Clinical Outcome in the Setting of Invasive Aspergillosis

Principal/Initiating Investigator: Marr, Kieren Pfizer WS484648 Period: 9/1/11-12/31/13  
A prospective, randomized trial comparing the efficacy and safety of voriconazole administered with therapeutic drug monitoring vs. standard dosing.

Principal Investigator: Shoham, Shmuel NIAID IRC-002 Period: 9/1/11-6/30/12  
A Randomized, Open-Label, Phase 2, Multicenter Safety and Exploratory Efficacy Study of Investigational anti-Influenza A H1N1 Immune Plasma for the Treatment of Influenza A H1N1 2009

Principal Investigator: Marr, Kieren Schering Plough PO5615 Period: 1/1/10-12/31/11  
Phase 1B Study of the Pharmacokinetics and Safety of Solid Oral Posaconazole in Subjects at High Risk for Invasive Fungal Infections

Principal Investigator: Marr, Kieren ADMA Biologics 002 Period: 10/1/11-6/30/12  
An open-label, multicenter study of RI-001 for prevention of progression of RSV upper respiratory tract disease in hematopoietic transplant patients

Principal Investigator: Shoham, Shmuel Astellas WSA-CS-008 Period: 9/1/11-6/30/13  
A Phase III, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of BAL8557 Versus a Caspofungin Followed by Voriconazole Regimen in the Treatment of Candidemia and Other Invasive Candida Infections

Principal Investigator: Shoham, Shmuel NIAID DMID 07-0036 Period: 9/1/11-8/31/13  
Optimizing Dosing of Colistin for Infections Resistant to all Other Antibiotics

Principal Investigator: Shoham, Shmuel Merck V212-011 Period: 10/1/11-12/31/15  
A Phase III Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of V212 in Adult Patients with Solid Tumor or Hematologic Malignancy

Principal Investigator: Marr, Kieren Schering Plough P05520 Period: 10/1/11-12/31/13  
Pharmacokinetics, Safety, and Tolerability of Intravenous Posaconazole Solution Followed by Oral Posaconazole Suspension (SCH 56592) in Subjects at High Risk for Invasive Fungal Infections

Selected remote (completed)

1998 – 2002 Voriconazole for therapy of invasive aspergillosis  
Pfizer research study  
P.I. Marr, FHCRC

2002 – 2006 Surveillance for invasive fungal infections in transplant recipients  
University of Alabama / CDC TRANSNET  
P.I. FHCRC Marr

2003 – 2005 Posaconazole for therapy of invasive fungal infections: Phase II  
Schering Plough research study  
P.I. Marr, FHCRC



2004 - 2007	PATH Alliance: Surveillance of invasive fungal infections Astellas P.I. FHCRC Marr; OHSU Investigator
2004 – 2007	NHBLI BMT CTN Protocol 0101: Voriconazole vs. fluconazole for prophylaxis against invasive fungal infections

## **RESEARCH ACTIVITIES (other)**

### **Academic Program Building & Leadership**

2008–current	Director, Transplant and Oncology Infectious Diseases Program, JHU
2008–2021	Director, Transplant and Oncology ID Clinical Research Center, JHU
2007–2008	Director, Transplant Infectious Diseases Program, OHSU
2007–2008	Director, Infectious Diseases Clinical Research Center, OHSU
1998–current	Principal Investigator, Translational Research in Mycology Laboratory
2016 – 2022	Vice Chair of Medicine for Healthcare Implementation, JHU

### **Drug Development and Regulatory Experience**

Principal Investigator, antifungal Phase I–IV clinical trials (1998–2018, detailed in funding section)

Member, IRB, Seattle Biomedical Research Institute (1998–2002)

Director, Clinical Trials Center: contracts, trial recruitment, design, performance, data evaluation (FHCRC 1998–2007; JHU 2008–current)

IND filed and held 2000–2004 (FHCRC)

Member, multiple Data Review Committees and Data and Safety Monitoring Boards (detailed below)

Designed and led multiple phase II–IV clinical trials, NIH and industry-funded (detailed below) FDA consultant for diagnostics (2010–2104)

Core faculty member, JHU center for drug safety (2010–2018)

Key consultant for numerous drug development efforts and advisory boards (detailed below)

Establishment of drug development plan for in-licensed drug (MycoMed–Novartis)

Established clinical development plan for two in vitro diagnostics in late-stage commercial development and presented FDA pre-510 (2016)

Developed Rezafungin prevention protocol(s) and represented to FDA and EU regulatory agencies (2017–2023)

Invited Speaker, FDA Workshop on Antifungal Resistance (May 2020)

Invited Speaker, FDA Workshop on Inhaled Antifungal Development (Sept 2020)

Invited Speaker, Cystic Fibrosis Foundation Fungal Workshop (Feb. 2021)

Invited Participant, Cystic Fibrosis Foundation Fungal Diagnostics Workshop (Sept. 2021)

Invited Participant, Advisory Board for Antifungal Prophylaxis, Abbvie (Nov. 2021)

Invited Participant, FDA workshop on Antifungals for Unmet Needs (2024)

Invited Participant, FDA workshop on Inhaled antimicrobials (2024)

### **Inventions, Patents, Copyrights**

U.S. Patent 20100326218: “Identifying a subject with an increased risk of invasive mold infection” Filed 9/26/08 (abandoned)

U.S. Provisional Application 16/154,016: “Molecular Identification of *Aspergillus* section fumigate species based on PCR-Restriction Fragment Length Polymorphism (RFLP) of Beta –Tubulin” (abandoned)

U.S. Patent 10,288,611: “Lateral flow device for diagnosing microbial infections” Issued 5/14/2019

U.S. Patent 9,915,657: “Diagnosis of Fungal Infections with a Urine Lateral Flow Device” Issued 3/13/18

U.S. Patent 10,107,822: “Interferon-gamma release assays for Diagnosis of Invasive Fungal Infections” Issued 10/23/18

U.S. Patent 15/882,278: “Optimizing Diagnostics for Galactofuranose Containing Antigens.” Issued 3/20/20

U.S. Patent 10,585,098: “Optimizing Diagnostics for Galactofuranose Containing Antigens.” Issued 5/20/20;

U.S. Patent continuation of 10,585,098, 11,070,380 Issued 8/3/2021

U.S. Patent 11,592,445: “OLFR90 specificity and methods of detection. Issued 2/28/2023

U.S. Provisional Application 62/833,957: “Methods and compositions using extracellular vesicles for the detection of disease and disorders.” Filed 4/15/19; PCT/US2020/028276 filed 4/15/2020 Pub. 10/22/2020, filed in EU, Japan, Australia, Canada

### **Technology Transfer / Entrepreneurship**

Founder, Life Sciences Consulting, LLC—a company focused on providing consultative services for development of antimicrobial drugs and devices (2011–current)

Co-founder, President and Director of Pearl Diagnostics, Inc. (previously MycoMed Technologies, LLC)—a JHU spin-off company developing diagnostics to identify early infections in vulnerable hosts (2014–current). Technology enables development of urine and other body fluid assays to assist diagnosis of lung infections, including those caused by fungi and bacteria, and assays that probe immune repertoire to identify latent and active infections.

Co-founder, President and Chief Medical Officer of Elion Therapeutics, Inc. (previously Sfunga)— a company developing 3<sup>rd</sup> generation polyene antifungals (2022 – current);

### **EDUCATIONAL ACTIVITIES**

#### **Teaching**

##### Classroom instruction

1999–2006 University of Washington Infectious Diseases fellow course

2000–2004 Fred Hutchinson Cancer Research Center BMT fellows course

2004–2006 University of Washington Human Biology 534 (lecturer medical mycology)

2013 JHU Drug Development Bootcamp

2014–2018 JHU Bootcamp for Biomedical Entrepreneurism

2021 JHU Carey Workshop for Entrepreneurs

##### Clinical

2013–2016 JHU Internal Medicine Barker Firm Faculty

CME (2003–)

- 2002 Invited Speaker, 42<sup>nd</sup> Annual International Conference of Antimicrobial Agents and Chemother
- 2003 Invited Speaker, University of California, San Diego, Infectious Diseases Grand Rounds, San Diego, CA
- 2003 Invited Speaker, University of California, San Francisco Infectious Diseases Grand Rounds, San Francisco, CA
- 2003 Invited Speaker, MD Anderson Cancer Center, Infectious Diseases Grand Rounds, Houston, TX
- 2003 Invited Speaker, Memorial Sloan Kettering Cancer Center Infectious Diseases Grand Rounds, NY, NY
- 2003 Invited Speaker, Brigham and Women's Hospital Infectious Diseases Grand Rounds, Boston, MA
- 2003 Invited Speaker, Critical Care Society Annual Meeting, San Antonio, TX
- 2003 Invited Speaker, Massachusetts General Hospital Infectious Diseases Grand Rounds, Boston, MA
- 2003 Invited Speaker, Boorhaeve Conference, Leiden, Netherlands
- 2003 Invited Speaker and Session Moderator, International Society for Human and Animal Mycoses, Paris, FR
- 2003 Invited Speaker, 43<sup>rd</sup> Annual IDSA
- 2003 Invited Speaker, Remington Annual Winter Conference in ID, Keystone, CO
- 2003 Invited Speaker, Infectious Disease 2003 Board Review Course, McClean, VA
- 2003 Invited Speaker, Focus on Fungal Infections, Maui, HA
- 2003 Invited Speaker, Canadian Bone Marrow Transplant Meeting, Halifax, NS
- 2003 Invited Speaker, American Society for Microbiology Annual Meeting
- 2003 Invited Speaker, American Society for Hematology Annual Meeting
- 2003 Invited Speaker, American Society for Blood and Marrow Transplant Annual Meeting, Keystone, CO
- 2004 Invited Speaker, John E. Bennett Forum on Deep Mycoses Study Design, NY
- 2004 Invited Speaker, 11<sup>th</sup> International Conference on Infectious Diseases, Cancun, MX
- 2004 Invited Speaker, Medicine Grand Rounds, Foothills Hospital, Calgary, Alberta, CA
- 2004 Invited Speaker, Combined BMT and ID Grand Rounds, Vancouver General Hosp, BC
- 2004 Invited Speaker, Pediatrics Grand Rounds, Children's Hospital Pittsburgh, PA
- 2004 Invited Speaker, University of Tennessee Medical Grand Rounds, Memphis, TN
- 2004 Invited Speaker, University of Rochester BMT Grand Rounds, Rochester, NY
- 2004 Invited Speaker, International Compromised Hosts Society, Granada, Spain
- 2004 Invited Speaker, American Society of Microbiology, New Orleans, LA
- 2004 Invited Speaker, Scott and White Medical Center, Medical Grand Rounds, TX
- 2004 Invited Speaker, 1<sup>st</sup> Advances against Aspergillosis Meeting, CA
- 2004 Invited Speaker, Infectious Disease 2004 Board Review Course, McClean, VA
- 2004 Invited Speaker (moderator), 43<sup>rd</sup> Annual IDSA, Boston, MA
- 2004 Invited Speaker, Memorial Sloan Kettering CRC ID Grand Rounds, NY
- 2004 Invited Speaker, 44<sup>th</sup> Annual ICAAC, Washington, DC
- 2004 Invited Speaker, ASH symposium on fungal infections, San Diego, CA
- 2005 Invited Speaker, moderator, Focus on Fungal Infections, Miami, FA

2005 Invited Speaker, University of Maryland ID Grand Rounds, Baltimore, MD

2005 Invited Speaker, University of Michigan ID Grand Rounds, Ann Arbor, MI

2005 Invited Speaker, Madigan Army Medical Center Medicine Grand Rounds, WA

2005 Invited Speaker, Infections in Cancer Symposium, MD Anderson Cancer Center, Houston, TX

2006 Invited Speaker, 8th International Symposium on Febrile Neutropenia, Athens, Greece

2006 Invited Speaker, American Society for Blood and Marrow Transplantation, Honolulu, Hawaii

2006 Invited Speaker, The Arizona Infectious Diseases Society Meeting, Sedona, Arizona

2006 Invited Speaker and Moderator, Focus on Fungal Infections, Las Vegas, Nevada

2006 Invited Speaker, 31<sup>st</sup> Annual Harvard and MGH ID of Adults Postgraduate Course, Boston, MA

2006 Invited Speaker, American Society for Microbiology, Orlando, FL

2006 Invited Speaker, American Society for Clinical Oncology, Atlanta, GA

2006 Invited Speaker and Moderator, 16<sup>th</sup> Annual International Society for Human and Animal Mycology Meeting, Paris, FR

2006 Invited Speaker, 14<sup>th</sup> Symposium on Infections in the Immunocompromised Host, Crans Montana, Switzerland

2006 Invited Speaker, Medicine Grand Rounds, Dartmouth Medical Center, NH

2006 Invited Speaker, Infectious Disease 2006 Board Review Course, McClean, VA

2006 Invited Speaker, 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA

2006 Invited Speaker, 44<sup>th</sup> Annual Infectious Diseases Society for America Meeting, Vincent Andriole ID Board Review Symposium, Toronto, Ontario

2006 Invited Speaker, Infectious Diseases Grand Rounds, Toronto General Hospital, Toronto, Ontario

2006 Invited Speaker, Infectious Diseases Grand Rounds, Maisson Rosemont Hospital, Montreal

2006 Invited Speaker, Infectious Diseases Grand Rounds, McGill Hospital, Montreal

2006 Invited Speaker, Infectious Diseases Grand Rounds, UCLA Medical Center, Los Angeles, CA

2006 Invited Speaker, Hematology Grand Rounds, Children's Hospital Los Angeles, CA

2006 Invited Speaker, Infectious Diseases Grand Rounds, Cedar Sinai Hospital, Los Angeles, CA

2006 Invited Speaker, Microbiology Grand Rounds, University of Nevada, Reno, Nevada

2006 Invited Speaker, NY Academy of Sciences, NY, NY

2007 Invited Speaker, American Soc Blood and Marrow Transplantation, Keystone, CO

2007 Invited Speaker, Society for Critical Care Medicine, Orlando, FL

2007 Invited Speaker, Focus on Fungal Infections, San Diego, CA

2007 Invited Speaker, 33<sup>rd</sup> Remington Winter Course in Infectious Diseases, Vail, CO

2007 Invited Speaker, Australasian Society for Infectious Diseases, Hobart, Tas, Australia

2007 Invited Speaker, Medicine Grand Rounds, University of Utah, Salt Lake City, UT

2007 Invited Speaker, American Society of Pediatrics (PAS) Meeting, Toronto, CA

2007 Invited Speaker, H. Lee Moffitt Cancer Center, BMT Grand Rounds, Tampa Fl

2007 Invited Speaker, St. Joseph Hospital Medical Grand Rounds, Bellingham, WA

2007 Invited Speaker, Infectious Disease 2007 Board Review Course, McClean, VA

2007 Invited Speaker, 45<sup>th</sup> Annual Infectious Diseases Society for America Meeting, Vincent Andriole ID Board Review Symposium, San Diego, CA

- 2007 Invited Speaker and Moderator, CME Satellite Symposium at 47<sup>th</sup> Annual Interscience Conf on Antimicrob Agents and Chemother, Chicago, IL
- 2007 Invited Speaker, Meet the Professor, 47<sup>th</sup> Annual Interscience Conf on Antimicrob Agents and Chemother, Chicago, IL
- 2007 Invited Speaker, Providence Hospital BMT Grand Rounds
- 2007 Invited Speaker, Oregon Society of Health System Pharmacists Meeting, Sun River, OR
- 2007 Invited Speaker, Oregon Health and Sciences University Medical Grand Rounds, OR
- 2008 Invited Speaker, American Soc Blood and Marrow Transplantation, San Diego, CA
- 2008 Invited Speaker, 9<sup>th</sup> ASM Conference on Candida and Candidiasis, NY
- 2008 Invited Speaker, 34<sup>th</sup> Remington Winter Course in Infectious Diseases, Sun Valley, ID
- 2008 Invited Speaker, University of Illinois Infectious Diseases Grand Rounds, Chicago, IL
- 2008 Invited Speaker, Chicago Area Mycology and Parasitology Meeting, Chicago, IL
- 2008 Invited Speaker, Harbor UCLA Infectious Diseases Grand Rounds, Los Angeles, CA
- 2008 Invited Speaker, American Transplant Congress Satellite Symposium, Toronto
- 2008 Invited Speaker and Moderator, 2008 International Congress of the Transplantation Congress, Sydney, Australia
- 2008 Invited Speaker, Infectious Disease 2008 Board Review Course, McClean, VA
- 2008 Invited Speaker, Meet the Professor, and Moderator, 48<sup>th</sup> Annual Interscience Conf on Antimicrob Agents and Chemother, Washington, DC
- 2008 Invited Speaker, 46<sup>th</sup> Annual Infectious Diseases Society of America, Washington, DC
- 2008 Invited Speaker, American Society for Hospital Pharmacists, Orlando, FL
- 2009 Invited Speaker, American Society for Blood and Marrow Transplantation, Tampa, FL
- 2009 Invited Speaker, 35<sup>th</sup> Remington Winter Course in Infectious Diseases, Steamboat Spring, CO
- 2009 Invited Speaker, Focus on Fungal Infections 19, Sanibel Harbor, FL
- 2009 Invited Speaker, Society for Healthcare Epidemiology of America 2009, San Diego, CA
- 2009 Invited Speaker, 2009 European Blood and Marrow Transplant Conference, Goteborg, Sweden
- 2009 Invited Speaker, Colorado Infectious Diseases Society of America Grand Rounds, Denver, CO
- 2009 Invited Speaker, American Society for Microbiology, Philadelphia, PA
- 2009 Invited Speaker, International Society for Human and Animal Mycoses, Tokyo, Japan
- 2009 Invited Speaker, International Conference on Chemotherapy, Toronto, Canada
- 2009 Visiting Professor, Drexel University College of Medicine's Institute for Molecular Medicine and Infectious Diseases Research Seminar Series, Philadelphia, PA
- 2009 Invited Speaker, Infectious Disease 2009 Board Review Course, McLean, VA
- 2009 Invited Speaker, 49<sup>th</sup> Annual Interscience Conf on Antimicrob Agents and Chemother, Phila, PA
- 2009 Invited Speaker, Vince Andriole Board Review Course, Infectious Diseases Society of America, 2009, Philadelphia, PA
- 2009 Invited Speaker, Infectious Diseases Grand Rounds, Enfant-Jesus Hospital, Quebec City, Quebec
- 2009 Invited Speaker, Infectious Diseases Grand Rounds, Hotel-Dieu Hospital, Quebec City, Quebec
- 2009 Invited Speaker, Medicine Grand Rounds, Trois-Rivieres Hospital, Trois Rivieres, Quebec
- 2009 Invited Speaker, Infectious Diseases Grand Rounds, McGill University Health Center, Montreal
- 2009 Invited Speaker, Medicine Grand Rounds, Maisonneuve-Rosemont Hospital, Montreal

- 2009 Invited Speaker, ID and BMT Grand Rounds, Ottawa Hospital, Ottawa
- 2009 Meet the Professor, Infectious Diseases Society of America 2009, Phila, PA
- 2010 Invited Speaker, Infectious Diseases Grand Rounds, UT Southwestern, Dallas, TX
- 2010 Invited Speaker and Session Moderator. Advances in Aspergillosis, Rome, IT
- 2010 Invited Speaker, 36<sup>th</sup> Remington Winter Course in Infectious Diseases, Vail, CO
- 2010 Invited Speaker, and Moderator Focus on Fungal Infections 20, New Orleans, LA
- 2010 Invited Speaker and Moderator, ASM Meeting on Candida and Candidiasis, Miami, FL
- 2010 Invited Speaker, Tumulty Topics in Clinical Medicine, Johns Hopkins, Baltimore, MD
- 2010 Visiting Professor, Department of Medicine, Montefiore Medical Center, NY, NY
- 2010 Visiting Professor, Departments of Medicine and Pathology, University of Cincinnati, Cinn, OH
- 2010 Invited Speaker, Infectious Disease 2010 Board Review Course, McLean, VA
- 2010 Invited Speaker, Meet the Professor, and Moderator, 50<sup>th</sup> Annual Interscience Conf on Antimicrob Agents and Chemother, Boston, MA
- 2010 Invited Speaker and Moderator, 48<sup>th</sup> Annual Infectious Diseases Society of America, Vancouver, British Columbia, Canada
- 2010 Invited Speaker, Alberta Infectious Diseases Society Annual Meeting, Banff, Alberta, Canada
- 2010 Invited Speaker, Infectious Diseases Grand Rounds, University of Calgary, Alberta, Canada
- 2011 Invited Speaker, Infectious Diseases Grand Rounds, New York University, NY, NY
- 2011 Invited Speaker, Gordon Research Conference on Fungal Immunology, Galveston, TX. (“Translating immunologic risks into prevention strategies in transplant recipients”)
- 2011 Visiting Professor, Case Western Reserve, Cleveland, OH
- 2011 Invited Speaker, CME-symposium at the European Blood and Marrow Transplant Meeting, Paris, France (“Management and Prevention of Invasive Fungal infections in Hematology”)
- 2011 Invited Speaker, “Infections in Neutropenic Patients; and “Infections in Stem Cell Transplant Recipients.” Infectious Diseases Board Review, MacLean VA
- 2011 Invited Speaker and Moderator, “Zygomycosis”, 51<sup>st</sup> Annual Interscience Conf on Antimicrob Agents and Chemother, Chicago, IL
- 2011 Invited Speaker, “Do Antifungals Work in a Persistently Neutropenic Patient?” Infectious Diseases Society of America, Boston, MA
- 2011 Invited Speaker, “Fungal Infections: 2011.” Infectious Diseases Association of California, Long Beach, CA
- 2012 Invited Speaker, “Treatment of Invasive Aspergillosis.” Canadian BMT Annual Meeting. Toronto, Ontario, Canada
- 2012 Invited Speaker, “Balancing Academic Clinical Practice and Research,” NIAID / IDSA Infectious Diseases Research Career Meeting, Bethesda, MD
- 2012 Invited Speaker, “Prevention of Invasive Fungal Infections: A Research Career,” NIAID / IDSA Infectious Diseases Research Career Meeting, Bethesda, MD
- 2012 Invited Speaker, “Assessing the Risk of Invasive Aspergillus Infections among Solid Organ and Stem Cell Transplant Recipients,” International Society for Human and Animal Mycoses, Berlin, Germany
- 2012 Invited Speaker, “Combination Antifungal Therapy for Invasive Aspergillosis,” International Society for Human and Animal Mycoses, Berlin, Germany
- 2012 Invited Speaker, “New developments and risks for IFIs in hematology patients,” “Integrated approach to diagnosis- biomarkers and their role”, “Combination therapy: Data vs. Instinct” Clinical Mycology Conference, Melbourne, Australia

- 2012 Invited Speaker, “Infections in Neutropenic Patients; and “Infections in Stem Cell Transplant Recipients.” Infectious Diseases Board Review, MacLean VA
- 2012 Invited Speaker, “Combination Antifungal Therapy for Aspergillosis;” Controversies in Fungal Infections XIX, London, UK
- 2012 Invited Speaker, “Antifungal therapy for *Aspergillus* colonization in CF.” 26<sup>th</sup> Annual North American Cystic Fibrosis Conference, Orlando, FL
- 2012 Invited Speaker, “Mono- vs. Combination Therapy for Treatment of Invasive Mold Infections- What do we know?” ID Week, San Diego, CA
- 2012 Invited Speaker, “Aspergillosis in Solid Organ Transplant Recipients.” XXIII Reunión del Grupo de Trabajo de Enfermedades Infecciosas (GTEI) of the SEMICYUC. Barcelona on November 17–18 2011
- 2012 Invited Speaker, “Opportunistic Infections.” 54<sup>th</sup> American Society of Hematology Meeting, Atlanta, GA
- 2013 Invited Speaker, “Cryptococcal disease,” “Fungal pneumonia.” 39<sup>th</sup> Remington Winter Course in Infectious Diseases, Beaver Creek, CO
- 2013 Invited Speaker, “Combination antifungal therapy: The controversies continue.” Fred Hutchinson Cancer Research Center Grand Rounds
- 2013 Invited Speaker, “Preventing infections in pediatric stem cell transplant recipients.” Pediatric Bone Marrow Transplant Society Meeting, Orlando, FL
- 2013 Invited Speaker, University of British Columbia Infectious Diseases Grand Rounds, Vancouver
- 2013 Invited Speaker, University of British Columbia Hematology Grand Rounds, Vancouver, BC
- 2013 Invited Speaker, University of Calgary Infectious Diseases Grand Rounds, Calgary AB
- 2013 Invited Speaker, University of Calgary Hematology Grand Rounds, Calgary AB
- 2013 Invited Speaker, University of Edmonton Infectious Diseases Grand Rounds, Edmonton, AB
- 2013 Invited Speaker, University of Edmonton Hematology Grand Rounds, Edmonton, AB
- 2013 Invited Speaker, “Infections in Neutropenic Patients; and “Infections in Stem Cell Transplant Recipients.” Infectious Diseases Board Review, MacLean VA
- 2013 Invited Speaker, “Antifungal Prophylaxis in HCT Recipients,” Transplant A – Z: Current predicaments, future solutions, ICAAC, Denver CO
- 2013 Invited Speaker, “Meet the Professor,” ICAAC, Denver CO
- 2014 Invited Speaker, “Treating Candida Bloodstream Infections” and Fungal Infections.” 40<sup>th</sup> Remington Winter Course in Infectious Diseases, Snowmass, CO
- 2014 Invited Speaker, “Non-culture methods for diagnosis of aspergillosis.” 24<sup>th</sup> European Congress of Clinical Microbiology and Infectious Diseases, Barcelona, Spain
- 2014 Invited Speaker, “Infections in Neutropenic Patients; and “Infections in Stem Cell Transplant Recipients.” Infectious Diseases Board Review, MacLean VA
- 2014 Invited Speaker, “Diagnosis of Invasive Fungal Infections” in "Establishing Best Practices for the Diagnosis and Management of Invasive Fungal Infections (IFIs)" at ICAAC, Washington, DC
- 2014 Invited Visiting Professor, Karolinska University Hospital, Huddinge, Stockholm
- 2014 Invited Speaker, Creativity and Innovation Workshop, JHU Carey School of Business
- 2014 Invited Speaker, “Prevention and Early Diagnosis of Fungal Infections,” 56<sup>th</sup> American Society of Hematology, San Francisco, CA
- 2015 Invited Speaker, “Fungal Diagnostics: A Tale of Two Births,” JHU Medical Grand Rounds

- 2015 Invited Speaker, “Current and future concepts in assessing risks for fungal infections in HCT recipients,” 2015 BMT Tandem Meeting, San Diego, CA
- 2015 Invited Speaker, “Neutropenic Fever,” American College of Physicians Meeting, Boston MA
- 2015 Invited Speaker, “Infections in Neutropenic Patients; and “Infections in Stem Cell Transplant Recipients.” Infectious Diseases Board Review, MacLean VA
- 2015 Invited Moderator, “Diagnostics for Aspergillosis,” at International Conference for Antimicrobial Agents and Chemotherapy, San Diego, CA
- 2015 Invited Speaker, Invasive Mycoses in Hematologic Malignancies: Disarming the Fungal Saboteur” at the American Society of Hematology Meeting, Orlando, Florida
- 2016 Invited Speaker, “Prevention of Invasive Fungal Infections,” at the American Society for Blood and Marrow Transplantation, Honolulu, Hawaii
- 2016 Invited Speaker, “Advances in Preventing Invasive Fungal Infections,” at the 1<sup>st</sup> Joel Meyers Memorial Symposium, Fred Hutchinson Cancer Center, Seattle, WA
- 2016 Invited Speaker, “Neutropenia and Related Syndromes; and “Infections in Stem Cell Transplant Recipients.” Infectious Diseases Board Review, MacLean VA
- 2016 The 3<sup>rd</sup> Gerald Medoff Visiting Professor, Washington University in St. Louis Department of Medicine Grand Rounds. “Transplant Infectious Diseases: The Paradox of Prevention”, November 2016, St. Louis, MO
- 2017 Invited Speaker, “New Emerging Diagnostics for Endemic Infections,” New Orleans, LA
- 2017 Invited Speaker, “Infections in Neutropenic Hosts” and “Infections in Bone Marrow Transplant Patients, Infectious Diseases Board Review Course, McLean, VA
- 2017 Invited Speaker, “Combination Antifungal Therapy for Fungal Infections,” ID Week, San Diego, CA
- 2018 Invited Speaker, “Neutropenia and Related Syndromes; and “Infections in Stem Cell Transplant Recipients.” Infectious Diseases Board Review, MacLean VA
- 2019 Visiting Professor, University of Pittsburg Division of Infectious Diseases, Pittsburg, PA
- 2019 Presidential Address, American Association for Clinical Investigation: “The Ownership Paradox: Nurturing Continuity and Change for the Future of ASCI,” Chicago, IL
- 2019 Invited Speaker, Infectious Diseases Society of New York Harold Neu Symposium: “Infections in Transplant Recipients” NY, NY
- 2019 Invited Speaker, Stony Brook University Hospital Department of Medicine Grand Rounds. “Transplant Infectious Diseases, The Paradox of Prevention.” Stony Brook, NY
- 2019 Invited Speaker and Moderator, European Congress of Clinical Microbiology and Infectious Diseases, “New Fungal Diagnostics,” and “Detection of Aspergillus galactofuranose containing antigens in urine.” Amsterdam, NL
- 2019 Invited Speaker and Moderator, 3<sup>rd</sup> Symposium on Infectious Diseases in the Immunocompromised Host. “New Antifungals.” Seattle, WA
- 2019 Invited Speaker, American Society for Microbiology. Detection of Aspergillus galactofuranose containing antigens in urine.” San Francisco, CA
- 2019 Invited Speaker, “Neutropenia and Related Syndromes; and “Infections in Stem Cell Transplant Recipients.” Infectious Diseases Board Review, MacLean VA
- 2020 Invited Speaker, Johns Hopkins DOM Grand Rounds: Covid
- 2020 Invited Speaker, 57<sup>th</sup> Annual William Hollaway ID Symposium, DE (postponed)
- 2020 Invited Speaker, Northwestern University Year in ID Symposium, IL (postponed)
- 2020 Invited Speaker, Vanderbilt University Grand Rounds (postponed)
- 2020 Invited Lecturer, 2020 Arthur White Lecturer at Indiana University (postponed)



- 2020 Invited Speaker and Moderator, FDA Conference on Antifungal Resistance
- 2020 Invited Speaker and Moderator, FDA Conference on Inhaled Antifungal Development
- 2020 Invited Speaker, “Neutropenia and Related Syndromes; and “Infections in Stem Cell Transplant Recipients.” Infectious Diseases Board Review, MacLean, VA
- 2021 Invited Speaker, American Medical Women’s Association (remote)
- 2021 Invited Speaker, Halloway Symposium, Christiana Healthcare (remote)
- 2021 Invited Speaker, “Neutropenia and Related Syndromes; and “Infections in Stem Cell Transplant Recipients.” Infectious Diseases Board Review (remote)
- 2022 Invited Speaker, “Neutropenia and Related Syndromes; and “Infections in Stem Cell Transplant Recipients.” Infectious Diseases Board Review (remote)
- 2023 Invited Speaker, “Infectious Diseases and Global Warming,” MIT Alumni Symposium
- 2023 Invited Speaker, “Making Medicines” Marine Biological Laboratory at Woods Hole, MA
- 2023 Invited Speaker, “Unmet Needs in Antifungals,” ASM/ESCMID AMR Conference, Boston, MA
- 2023 Invited Speaker, “Neutropenia and Related Syndromes; and “Infections in Stem Cell Transplant Recipients.” Infectious Diseases Board Review, MacLean, VA

**Mentoring (pre- and post-doctoral, research mentor)**

- 1999 Michael Koudadoust, MD, PhD, Undergraduate student, laboratory research, Current: University of Michigan
- 1999–2000 Tige Rustad, PhD, Current position: Postdoctoral Fellow, SBRI, UW
- 1999–2006 S. Arunmohzi Balajee, PhD, Current position: Chief, Molecular Mycology Laboratory, Centers for Disease Control, Atlanta, GA
- 2000 Laura Delbridge, Undergraduate student, laboratory research
- 2003 Timothy Yaw Bediako, Undergraduate student, laboratory research
- 2002–2003 Christopher Graber MD, Medical resident research project (U. Washington)
- 2002–2003 Benjamin Musher MD, Medical resident research project (U. Wash), Current: U Penn
- 2002–2004 Alexander Imhof MD, Visiting post-doctoral fellow, FHCRC
- 2003–2004 Anja Gugel MD, Visiting post-doctoral fellow, FHCRC
- 2003–2005 Anil Panackal, MD, Infectious Diseases Senior Fellow, U. Washington. Current: Investigator, National Institutes of Health, Bethesda, MD
- 2003–2007 Geoffrey Gersuk PhD, Current position: Senior Post-doctoral Fellow, FHCRC
- 2004–2006 Arlo Upton, MD, Current position: Clinical Microbiologist, Auckland City Hospital, Auckland, NZ
- 2004–2013 Janet Staab, PhD, Current position: Assistant Professor, Johns Hopkins University
- 2005–2008 Penelope Barnes MBBS PhD, Current position: Assistant Professor, OHSU
- 2007–2008 Kevin Winthrop MD MPH, Current position: Assistant Professor, OHSU
- 2007–2008 Lynne Strasfeld MD, Current position: Assistant Professor, OHSU
- 2007 Carol Garcia-Vidal, Current position: Medicine resident, Barcelona, Spain
- 2007–2021 Darin Ostrander PhD, Current position: Faculty Research Associate, Medicine, Johns Hopkins University
- 2008–2010 Aruna Subramanian MD, Current position: Assistant Professor, Stanford University

- 2008–2013 Dennis Neofytos MD, Current position: Associate Professor, Beth Israel Medical Center, Boston, MA
- 2008–2011 Carolyn Alonso MD, Infectious Diseases Fellow, Johns Hopkins Univ. Current position: Assistant Professor, Beth Israel Medical Center, Boston, MA
- 2010–2012 Simon Dufresne MD, Postdoctoral Graduate Fellow, Johns Hopkins Univ.; Current position: Assistant Professor, Hopital Maisonneuve-Rosemont, Quebec
- 2011 Eddie Byrnes PhD, Postdoctoral Graduate Fellow, Johns Hopkins Univ.; Current position:
- 2012 Rick LaRue MD, Infectious Diseases Fellow, Johns Hopkins University; Current Position: Assistant Professor, Vanderbilt University
- 2013–2016 Christine Durand MD, Assistant Professor, Johns Hopkins University
- 2014 Sehnaz Ozyavuz Alp MD, Visiting Physician from Turkey (JHU)
- 2014 Cristina Royo MD, Visiting Physician from Spain (JHU)
- 2014–2020 Seema Mehta MD, Clinical Associate (JHU)
- 2015–2017 Mona Al Fares MD, Transplant and Oncology ID Research and Clinical Fellow
- 2015 Jane Wang, JHU Medical Student: Medical entrepreneurship summer intern
- 2015–2021 Maria (Veronica) Dioverti-Prono, Clinical Associate(JHU)
- 2016–2018 Purba Gupta, Visiting Physician, JHU
- 2018–2021 Nitipong (Nate) Permpalung MD MPh, Clinical Associate (JHU)

#### Thesis committees

- 2001 Stephanie Owens, MD, Graduate student, Human Biology 599 ISMS thesis, with honors
- 2004 Thaochi Do, Undergraduate student UW Microbiology 496
- 2007 Cara Varley, Master's in Public Health program, OHSU
- 2014 Ola Blennow, International PhD Dissertation Opponent, Karolinska University Hospital, Huddinge, Stockholm
- 2015 Victoria Halperin Kuhns, Microbiology and Immunology PhD Thesis committee, JHU Bloomberg School of Public Health

#### Training grant participation

- 1998–2007 University of Washington; Pathogenesis in infectious diseases (NIH T32)
- 2007–2008 Oregon Health and Science University; Pulmonary immunology (NIH T32)
- 2008–2021 JHU Infectious Diseases (NIH T32)
- 2009–2021 Director, JHU GME-accredited Transplant and Oncology Infectious Diseases Fellowship, The Johns Hopkins University School of Medicine
- 2012–2016 JHU Neuro-infectious diseases (NIH T32)

#### **University Educational Program Building / Leadership**

- 2008 Director, Portland VA Medical Center Transplant Infectious Diseases Fellowship
- 2008–2021 Director, Transplant and Oncology Infectious Diseases Program, The Johns Hopkins University School of Medicine

2008–2016 Program Liaison, Department of Medicine – Carey School of Business, Discovery 2 Market Program

### **Educational Program Building / Leadership: Conference and Professional Organization Activities**

2001–2004 Executive Committee, Immunocompromised Host Society  
2002–2006 Program Committee, Infectious Diseases Society of America  
2009 Conference organizer: Candida and Candidiasis Conference  
2009 Conference organizer: 36<sup>th</sup> Remington Winter Course in Infectious Diseases 2009  
2012 Conference organizer: Candida and Candidiasis Conference 2012  
2012 Steering committee: International Society for Human and Animal Mycoses, 2012  
2016 – current Steering Committee, Fred Hutchinson Cancer Research Center NIH T32  
2018 – current. Steering Committee, GWU Infectious Diseases Board Review Course  
2023. Consultant to Mayo Clinic Department of Medicine, Phoenix, AR

### **CLINICAL ACTIVITIES**

#### **Certification (Include Board, Number, Date, and Recertification)**

1996 National Board of Medical Examiners, Internal Medicine  
1998 ABIM, Infectious Diseases  
2009 ABIM, Infectious Diseases (recertification)  
2021 ABIM, Infectious Diseases (recertification)

#### **Licenses (Include State, Date, Status, Number, and Renewal Date)**

1993–1996 North Carolina  
1996–2007 Washington  
2007–2008 Oregon  
2008–current Maryland

#### **Clinical (service) responsibilities**

1999–2002 Attending Physician, Infectious Diseases, Virginia Mason Medical Center  
1999–2007 Attending Physician, Infectious Diseases, Seattle Cancer Care Alliance, Seattle, WA  
1999–2007 Attending Physician, Internal Medicine, University of Washington, Seattle, WA  
1999–2007 Attending Physician, Medicine, Infectious Diseases, Harborview Hospital, Seattle, WA  
1999–2002 Attending Physician, Infectious Diseases, Virginia Mason Medical Center  
2007–2008 Attending Physician, Oregon Health and Science University, Portland, OR  
2008–current Attending Physician, Transplant and Oncology ID, Johns Hopkins Hospital, Baltimore, MD  
2012–2016 Member, JHU Barker Firm Faculty

#### **Clinical program building and leadership**

- 2007–2008 Director, Transplant Infectious Diseases, Oregon Health Science University, Portland, OR  
 2008 Director, Transplant and Oncology Infectious Diseases Program, The Johns Hopkins University School of Medicine, Baltimore, MD

## **ORGANIZATIONAL ACTIVITIES**

### **Institutional Administrative and Committee Appointments**

- 1998–2007 FHCRC Infectious Diseases standard practice committee  
 2001–2007 Member, Institutional Review Board, Seattle Biomedical Research Institute  
 2001–2007 Member, Seattle Cancer Care Alliance Infection Control Committee  
 2002 Member, FHCRC Protocol Review and Monitoring System Advisory Group  
 2003–2007 Member, FHCRC Research Ethics Education Oversight Committee  
 2007–2008 Director, Transplant Infectious Diseases Program, OHSU  
 2007–2008 Director, Infectious Diseases Clinical Research Center, OHSU  
 2008–2018 Program Liaison, JHU Department of Medicine – Carey School of Business, Discovery 2 Market Program  
 2009–2016 Co-director, Oncology Infectious Diseases committee, JHMI  
 2009–2012 Member, JHH P&T Antibiotic Subcommittee  
 2009–2022 Member, Infectious Diseases Subcommittee for Department of Medicine Professional Performance Evaluation  
 2010 Member, Ad hoc sub-committee for professorial promotion (SOM)  
 2012–2016 Member, Transplant Infectious Diseases committee, JHMI  
 2012–2022 Core faculty, Johns Hopkins Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health  
 2013 Member, JHU CME Advisory Board  
 2013 Member, JHU President’s faculty focus group on technology commercialization  
 2015–2022 Member, Faculty Advisory Group for Johns Hopkins Technology Ventures  
 2015 Member, Biomarkers and Diagnostic Advisory Board Meeting, Johns Hopkins Institute for Clinical and Translational Research  
 2016–2022 Member, Leadership Committee for Vice Chairs, Department of Medicine, Johns Hopkins University School of Medicine  
 2016–2022 co-Leader, Innovation and Commercialization in Medicine (IncMed), Department of Medicine, Johns Hopkins School of Medicine  
 2019–2022 Member, Advisory Committee for Faculty Commercialization and Entrepreneurship, Johns Hopkins School of Medicine  
 2020–2022 Member, JHMI Therapeutics and Clinical Trials for COVID-19

### **Extramural Service: Empowering Women in Medicine**

- 2012–2022 Member, JHU Office of Women in Science and Medicine  
 2013–2022 Member, JHU Women’s Task Force  
 2020–2022 Member, Provost Committee for Sexual Violence

2020–2022 Speaker, JHU Women in Infectious Diseases— “Eyes Wide Bare: Microaggressions and the Hidden Forces that Reveal and Propagate Everyday Bias in the Workplace”

### **Extramural Service: Editorial Boards**

2001–2004 Transplant Infectious Diseases  
2001–2008 Antimicrobial Agents and Chemotherapy (editorial board)  
2002–2006 Clinical Microbiology Reviews (editorial board)  
2002–2021 Up to Date in Infectious Diseases (Section Editor)  
2007–2009 Faculty of 1000 Medicine (faculty contributor)  
2009–2011 Current Infectious Disease Reports (editorial board)  
2009–2011 Virulence (editorial board)  
2011–2014 Current Infectious Disease Reports (Editor in chief)

### **Extramural Service: Advisory Committees, Review Groups and Study Sections**

#### Study sections

2002 Ad Hoc Reviewer, Canadian Research Council  
2004 Ad Hoc Reviewer for NIH study sections:  
Special interests study section ZAI1 HSD-M M2, (3/2004)  
Innate Immunity Program Project Review, ZAI1-GLM-M-S1 (5/2004)  
Special Emphasis Panel ZRG1-IDM-N-90S (6/2004)  
2005–2009 Member of NIH study section DDR (Drug Development and Antimicrobial Resistance);  
2008– co-chair  
2006 Ad Hoc Reviewer for NIH study section IDM-M  
2008 Ad Hoc Reviewer for NIH study section AZI1 MP-1  
2008 Ad Hoc Reviewer, UK Medical Research Council  
2008 Ad Hoc Reviewer, NIH study section Opportunistic Infections and Cancer study section  
(AOIC)  
2009 Ad Hoc Reviewer, Infectious Diseases Clinical Research Program, Uniformed Services  
University of the Health Sciences  
2009 Ad Hoc Reviewer, ZRG1 IDM-K Grand Opportunity grants  
2009 Ad Hoc Reviewer, ZRG1 IDM-T Grand Opportunity grants  
2010–2012 Member of the CSR college of Reviewers  
2012–2013 Member of the Mycology Consultant Network, Centers for Disease Control  
2012 Ad Hoc Reviewer, NIH study section small business review ZRG1 IDM-U  
2012 Ad Hoc Reviewer, NIH study section small business review IMM-N  
2016 Ad Hoc Reviewer, NIH study section for SBIR contract proposals ZAI1-PA-M-C1

#### International/National Advisory Committees and Review Groups

2000–2006 Member of Scientific Steering Committee, Immunocompromised Host Subcommittee for  
Oncology/BMT, NIH Bacteriology and Mycoses Study Group

2000–2002	Immunocompromised Host Society, Mycology Initiative Advisory Board, Co-Chair, Cancer and BMT panel
2001–2007	Member of Steering Committee, CDC and TRANSNET Fungal Infection Surveillance in Transplant Patients
2001–2004	Member of Program Committee, Infectious Diseases Society of America
2001	Member of Steering Committee, CDC Network for Prevention of Opportunistic Infections after HSCT
2002	Member of Fungal Protocol Committee, NHLBI BMT Clinical Trials Network
2002–2006	Member of Executive Council, Immunocompromised Host Society
2004–2006	Member of International Scientific Committee, International Society for Human and Animal Mycoses Meeting, 2006
2004–2007	Member, IDSA consensus panel for Invasive Aspergillosis
2005–2007	Member of Advisory Panel for Development of Therapies for Fungal Infections, American Thoracic Society
2005	Member of Scientific Advisory Board, Prospective Antifungal Therapy (PATH) Alliance
2006–2008	Member, Infectious Disease Society of America (IDSA) Consensus Panel for Definition of Invasive Fungal Disease
2006–	Member of the Infection/Immune Reconstitution Committee, NHLBI BMT Clinical Trials Network
2007	Chair, Fungal Infection Working Group, American Society for Blood and Marrow Transplantation / CDC Guidelines Committee
2008	Member of International Scientific Committee, International Society for Human and Animal Mycoses Meeting, 2009
2008–2014	Mycoses study group / FDA advisory panel for diagnostics
2008–2014	National Comprehensive Cancer Network Prevention and Treatment of Cancer-Related Infections Panel
2009	American Society of Clinical Oncology Guideline Panel for Outpatient Management of Fever During Neutropenia
2013–2015	Member and Director of Immunosuppressed hosts group, Antibiotic Resistance Leadership Group

### **Membership in Professional Societies**

1998–current	American Society for Microbiology
1999–current	International Immunocompromised Host Society
1999–current	Infectious Disease Society of America (Program Committee Member, 2000–04)
1999–2013	International Society for Human and Animal Mycology
2000–2013	Medical Mycology Society of the Americas
2000–current	Mycoses Study Group
2008–current	American Society of Transplantation
2009–current	Member, American Society for Clinical Investigation (by vote)
2009	The Transplantation Society: Women Leaders in Transplantation (founding member)

2018–current Member, Association of American Physicians (by vote)

**Conference Organizer, Session Chair (2004–)**

- 2004 Invited Speaker (moderator), 43<sup>rd</sup> Annual IDSA, Boston, MA
- 2005 Invited Speaker, moderator, Focus on Fungal Infections, Miami, FA
- 2006 Invited Speaker and Moderator, Focus on Fungal Infections, Las Vegas, Nevada
- 2006 Invited Speaker and Moderator, 16<sup>th</sup> Annual International Society for Human and Animal Mycology Meeting, Paris, FR
- 2007 Invited Speaker and Moderator, CME Satellite Symposium at 47<sup>th</sup> Annual Interscience Conf on Antimicrob Agents and Chemother, Chicago, IL
- 2007 Invited Speaker, Meet the Professor, 47<sup>th</sup> Annual Interscience Conf on Antimicrob Agents and Chemother, Chicago, IL
- 2008 Invited Speaker and Moderator, 2008 International Congress of the Transplantation Congress, Sydney, Australia
- 2008 Invited Speaker, Meet the Professor, and Session Moderator, 48<sup>th</sup> Annual Interscience Conference on Antimicrob Agents and Chemother, Chicago, IL
- 2010 Invited Speaker and Session Moderator. Advances in Aspergillosis, Rome, IT
- 2010 Invited Speaker, and Moderator Focus on Fungal Infections 20, New Orleans, LA
- 2010 Invited Speaker and Moderator, ASM Meeting on Candida and Candidiasis, Miami, FL
- 2011 Invited Speaker and Moderator, “Zygomycosis”, 51<sup>st</sup> Annual Interscience Conf on Antimicrob Agents and Chemother, Chicago, IL
- 2012 Session Moderator, Diagnostics in mycology in the light of molecular tools. International Society for Human and Animal Mycoses, Berlin, Germany
- 2013 Invited Moderator, ID Week, San Francisco, CA
- 2014 Invited Moderator, 56<sup>th</sup> American Society of Hematology, San Francisco, CA
- 2015 Invited Moderator, 2015 BMT Tandem Meeting, San Diego, CA
- 2016– Symposium Organizational Committee, Fred Hutchinson Symposium on Infectious Diseases in the Immunocompromised Host

External Consultancies (limited from >100 consultancies and/or advisory board memberships, since 2006)

- 2006 Data and Safety Monitoring Board, Antifungal prophylaxis trial, Schering Plough Corp
- 2006 Pfizer Anti-infective global advisory board
- 2006–2008 Advisory Board, Nektar Therapeutics
- 2007–2009 Astellas Pharma PATH Alliance advisory board
- 2007 Enzon Pharmaceuticals Antifungal advisory board
- 2007–2011 Consultant and Protocol committee member, Basilea Pharmaceutica
- 2007 Consultant and member Global Anti-infective Advisory Board, Pfizer Pharmaceuticals
- 2007 Antifungal Advisory Board, Merck Pharmaceuticals
- 2007–2010 Oncology Advisory Board, Merck Pharmaceuticals
- 2008–2011 Biomarker development advisory board, Merck Pharmaceuticals

2008	Antifungal Global Advisory Board, Pfizer Pharmaceuticals
2009	Novartis Oncology Advisory Board, Novartis Pharmaceuticals
2009–2018	U.S. Multidisciplinary Advisory Board, Merck and Co
2010	Consultant, Evolva
2010	Consultant, PrevAbR
2011	Advisory Board Member, Merada Therapeutics
2011	Advisory Board Member, Optimer Pharmaceuticals
2012–2016	Consultant and Advisory Board Member, Astellas Pharma Global Development
2012	Member, Merck’s Investigator Consultant Network
2012	Clinical Advisory Board member, Talbot Advisors
2013	Advisor, 5am Ventures
2014–2017	Advisory Board, Cidara Therapeutics
2014–2018	Consultant, Chimerix Inc.
2015	Consultant, Genentech
2015–2016	Consultant and member of Adjudication Committee, Merck Pharmaceuticals
2015–2016	Consultant, Revolutions Medicine (REVMed)
2014	Member, Theravance Biopharma Antibiotics, Inc. Immunocompromised Patient AB
2015	Advisor, Theravance Biopharma Antibiotics Strategic Advisory Board
2015	Member, Cubist Pharmaceuticals Advisory Board
2015–2017	Advisor, F2G Ltd
2015	Advisor, Matinas BioPharma
2016	Advisor, Incyte Pharmaceuticals
2016–2017	Consultant, Scynexis Biopharma
2016–2020	Advisor, Amplyx Biopharma
2017	Consultant, RTI Surgical
2017–current	Scientific Advisory Board, Cidara Therapeutics
2018–2020	Advisor, California Institute for Regenerative Medicine
2019–2020	Advisor, Entaka Therapeutics
2019–2021	Scientific Advisory Board, Sfunga Therapeutics

## **RECOGNITION**

### **Honors and Awards**

#### Undergraduate

1986	Cancer Federation Scholarship
1987	California State University Academic All-Stars
1987	Vice-President, Omicron Theta Epsilon, Biology Honors Society
1988	Normal Volunteer program, National Institutes of Health

#### Graduate



- 1993 Alpha Omega Alpha, member
- 1993 Hahnemann Club Award (Medical student most respected by students and faculty)
- 1993 Hahnemann Hospital Association Award
- 1993 American Medical Women's Association Janet Glasgow Memorial Citation
- 1993 Measy Scholarship (Top 10% medical school class)
- 1993 Laughlin Scholarship (Top 5% medical school class)

Postdoctoral

- 1996 Assistant Chief Resident, Internal Medicine, Duke University School of Medicine
- 1997 George McCracken Infectious Disease Fellow Award, ICAAC
- 1998 National Federation of Infectious Diseases, John P. Utz Medical Mycology Fellowship
- 1998 National Institutes of Health Mentored Scientist Grant

Faculty

- 2002 National Institutes of Health Clinical Research Loan Repayment Award
- 2004 National Institutes of Health Clinical Research Loan Repayment Award (2<sup>nd</sup>)
- 2009 American Society for Clinical Investigation (by nomination)
- 2011 Fellow, Infectious Diseases Society of America (by nomination)
- 2012–2019 America's Best Doctors (peer vote, annual)
- 2015 Voted one of World's Most Cited Researchers of 2015 (top 1% in 20 scientific disciplines), Thomson Reuters
- 2015, 2019 Voted one of the World's Most Influential Scientific Minds, Thomson Reuters
- 2016 President, American Society for Clinical Investigation (2017–2020)
- 2018 Member, Association of American Physicians (by vote)
- 2019 Medical Mycology Society of America Billy Cooper Award for Career Achievement
- 2020 Stanford University and Clarivate Analytics World's Most Cited Researchers (top 0.1%)